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Abstract 
Christianna Stack   
The Role of Palladin in Pancreatic Cancer 
(Under the direction of Dr. Carol A. Otey) 
 
Palladin is a phosphoprotein with a role in regulating the actin cytoskeleton.  Recently, 
palladin was identified as being overexpressed and mutated in a form of familial pancreatic 
cancer, an extremely lethal disease.  Protein expression studies indicated that palladin was 
overexpressed in the tumor cells, but immunohistochemistry data from a separate study 
showed that palladin was actually overexpressed in the non-neoplastic stroma of a pancreatic 
tumor.  The goal of this study was to determine which cell type overexpressed palladin using 
various palladin antibodies.  We found that the fibroblasts in the stroma of a pancreatic tumor 
overexpressed multiple isoforms of palladin.  The palladin expression occurs in a population 
of fibroblasts in the tumor microenvironment known as tumor-associated fibroblasts.  These 
cells resemble the fibroblasts present in healing wounds, a cell type where palladin is also 
expressed.  The consequence of palladin upregulation in these cells in the context of a 
pancreatic tumor is unknown. 
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Introduction 
 In this thesis, I will discuss the results of a study that examined the role of an actin-
binding protein, palladin, in pancreatic cancer.  To put these results into context, I will start 
with an introduction of the actin cytoskeleton and its regulation, and also how the 
cytoskeleton contributes to the behavior of cells.  I will then summarize palladin’s role in 
organizing the cytoskeleton and in cell behavior, determined through multiple studies with 
animal and cultured cell systems.  The last part of this introduction will focus on the 
relationship between cells in a tumor and the cells surrounding the tumor, or the 
microenvironment, and how this relationship might contribute to cancer progression and 
metastasis. 
 
The Actin Cytoskeleton 
 The actin cytoskeleton plays a vital role in virtually every aspect of cell behavior, 
from maintenance of basic structure to motility and the integration of signaling pathways.  It 
is composed of a highly dynamic network of filaments, and these filaments interact with a 
large number of accessory proteins to perform tasks both at the single cell level and in 
concert with other cells. Three of the fundamental functions of the actin cytoskeleton are 
regulation of adhesion, motility, and contractility.   Defects in the actin cytoskeleton can have 
widespread effects; specifically, developmental abnormalities, insufficient wound healing, 
and even enhanced migration of tumor cells.  The cytoskeleton field has advanced 
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dramatically in recent years, which has led to important new insights into the function and 
complexity of this subcellular component. 
 At a basic level, actin is a highly conserved globular protein that exists in two forms 
in a cell, monomeric, or G-actin, and filamentous, or F-actin.  G-actin monomers assemble 
into helical filaments upon activation by ATP exchange, and can eventually form higher 
order structures with multiple filaments, a property that allows actin to form protrusions or a 
contractile apparatus.  These filaments remain in a constant state of flux throughout their 
lifetime, with monomers adding at one end while simultaneously depolymerizing at the other 
end, particularly at the leading edge of a migrating cell, and this directional growth is known 
as “actin treadmilling.” Originally this phenomenon was described in microtubules (Margolis 
and Wilson, 1978), but was later described in actin filaments as well (SL  Brenner and Korn, 
1983; S.L. Brenner and Korn, 1979; Rzadzinska et al., 2004; Schmidt et al., 2002).   
The spontaneous polymerization of actin into filaments is a thermodynamically 
unfavorable process, and accordingly, a class of proteins known as “nucleation factors” bind 
to actin monomers and promote polymerization of filaments.  The classical actin nucleation 
factor is the Arp2/3 complex, which is composed of seven polypeptides, two of which, Arp2 
and Arp3, are proposed to mimic an actin dimer in order to promote polymerization (Chhabra 
and Higgs, 2007).  For Arp2/3 to build an actin filament, it must be activated by members of 
a class of nucleation promoting factors such as WASp (Machesky and Insall, 1998) and Scar 
(Machesky et al., 1999).  Once a filament has formed, this nucleation factor remains at one 
end of the filament, establishing the inherent polarity that characterizes filaments and their 
resulting structures.  Actin filaments have been characterized as having a pointed end and a 
barbed end due to studies with electron microscopy that showed subfragments of myosin 
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decorating actin filaments in a conformation that resembled an arrowhead (Begg et al., 1978).  
This phenomenon proved to be very consistent, and the designation has remained as a way to 
describe polarity of the filaments.  Arp2/3 remains at the pointed, or minus end, where 
depolymerization occurs, and polymerization continues at the barbed, or plus end.  A unique 
feature of the Arp2/3 complex is that it can also bind to the sides of existing filaments and 
polymerize new filaments at 70° degree angles from the pre-existing filament; the resulting 
network is called the “dendritic network” (Svitkina and Borisy, 1999).  This is one form of an 
actin array that is able to accomplish a task in a cell; with dendritic networks, their assembly 
can result in the formation of cell protrusions such as lamellipodia (Svitkina and Borisy, 
1999) and membrane ruffles.  Aside from Arp2/3, formin proteins act as nucleators and also 
aid in the formation of actin arrays (Gupton et al., 2007; Kovar et al., 2006). 
 Once actin-based structures are initiated by the activity of nucleating factors, they are 
regulated by a vast number of actin-binding proteins in the form for actin bundlers, cross-
linkers, polymerizers and depolymerizers. The polymerization and depolymerization of actin 
filaments is regulated by the monomer-binding proteins and the capping and severing 
proteins (Pollard and Cooper, 1986).  Profilin-1 binds to the G-actin monomers in the pool of 
free actin throughout the cell.  This protein is able to enhance the exchange rate of ATP 
bound to actin, inhibit the ATPase that works on actin monomers, and interestingly, can also 
inhibit polymerization (Blanchoin et al., 2000; Kinosian et al., 2002; Pollard and Cooper, 
1986). Additionally, profilin-1 binds multiple regulatory molecules, such as the 
phosphatidlylinositides PIP2 and PIP3.  Binding to PIP2 and PIP3 decreases its actin-binding 
activity (Pollard and Cooper, 1986).  Profilin-1 also interacts with members of protein 
families essential for cell migration, namely VASP, WASP/WAVE, and mDia (Zou et al., 
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2007).  Interestingly, profilin is only able to exert its effects on actin monomers, as it does 
not have the same effect on cross-linked dimers of actin (Pollard and Cooper, 1986).  When 
there are no barbed ends available for polymerization, profilin then acts as a monomer 
sequestering protein (Paavilainen et al., 2004). 
 ADF/cofilin is another monomer-binding protein that is also able to bind F-actin, 
augmenting the scope of its activities within the actin cytoskeleton.  Part of a larger pathway 
containing kinases and phosphatases that regulate cofilin in response to stimuli like EGF, 
TGF-α, SDF-1, and heregulin (Wang et al., 2007), cofilin itself is essential for generating 
free barbed ends of actin filaments and for actin filament turnover in multiple cell types, 
including breast cancer cells and fibroblasts (Wang et al., 2007).  As actin filaments grow, 
the monomers closer to the pointed end begin to hydrolyze their ATP to ADP; cofilin has a 
high affinity for ADP-F-actin and binding to these monomers causes a twist in the filament 
that leads to thermodynamic instability and subsequent severing of the actin filament, hence 
the additional designation of cofilin as a “severing protein” (Paavilainen et al., 2004).  There 
are also capping proteins that simply cap actin filaments.  They block the barbed end of a 
filament and prevent further polymerization and treadmilling (Pollard and Cooper, 1986).   
 
Types of Actin Arrays and Their Regulation by Actin-Binding Proteins  
Through nucleation by Arp2/3, formins, and mDia and monitoring by the monomer-
binding proteins, dendritic arrays of actin filaments are able to form sheet-like structures that 
assist in cell spreading and motility.  Lamellipodia and peripheral ruffles are membrane 
protrusions formed by the activities of dendritic arrays, and allow for cell movement and 
spreading (Chhabra and Higgs, 2007).  Lamellipodia remain attached to a substrate by actin-
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based adhesions that contain adhesion receptors from the integrin family and accessory 
proteins including vinculin, talin, and paxillin.  Adding to the complexity of the lamellipodial 
actin network is the existence of two separate dendritic actin arrays within the structure, the 
lamellipodium, which is at the very leading edge of a motile cell, has random, short-lived, 
and fast-moving protrusions which are only weakly adherent (Le Clainche and Carlier, 2008; 
Papakonstanti and Stournaras, 2008), and the lamella, which is the site of productive cell 
body movement and therefore has more stable and long-lived actin protrusions  
(Papakonstanti and Stournaras, 2008) and stronger cell adhesions.  For a cell to move along a 
substrate there must be coordinated activities within the actin cytoskeleton that involve all of 
its basic functions of adhesion, contractility, and motility.  In the case of lamellipodia, actin-
based adhesions must be assembled and disassembled, contractile fibers must contract and 
relax in order to give a cell forward momentum, and the dendritic array at the leading edge of 
the movement must be constantly severing and polymerizing new filaments to continue 
directional movement. 
 Actin bundles are another important type of actin array.  Bundles are, simply put, 
linear multi-filament arrays held together by actin-binding proteins like fascin, villin and 
fimbrin. Bundling proteins act by binding to the sides of adjacent actin filaments, lying in 
between them throughout the length of the filaments in a punctate fashion (Pollard and 
Cooper, 1986). Actin bundles are an essential part of structures like filopodia, the finger-like 
protrusions with multiple functions in cells; microvilli, the protrusions most recognized for 
being on the surface of intestinal epithelial cells; and the contractile rings that act to pinch off 
the membrane during cytokinesis.  Bundles can either be parallel or anti-parallel in 
orientation. Parallel bundles consist of a group of filaments where all of the barbed ends and 
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pointed ends of the filaments face in the same direction.  An anti-parallel filament, on the 
other hand, has filaments of opposite orientation side by side. This type of array becomes 
especially important for generation of contractile forces.  Like dendritic arrays, bundles are 
also interacting with monomer-binding proteins, polymerizers, and depolymerizers; for 
example, formation of filopodia involves barbed end elongation and nucleation, and 
maintenance requires constant actin treadmilling at both ends in addition to bundling 
(Chhabra and Higgs, 2007).   
To add to the complexity of actin bundles, a third group of proteins, known as cross-
linkers, interacts with both parallel and anti-parallel arrays.  Cross-linking proteins are 
characterized as being divalent molecules that can bind the sides of two different actin 
filaments, and unlike bundling proteins, their activities can form three-dimensional actin 
structures (Pollard and Cooper, 1986).  The shape of the divalent molecule is important for 
the types of 3-D actin structures they can produce (Kureishy et al., 2002). The members of 
the α-actinin family of proteins are known to be canonical actin bundling and cross-linking 
proteins.  There are four isoforms of α-actinin, isoforms 2 and 3 are restricted to cardiac and 
striated muscle, while isoforms 1 and 4 are expressed in non-muscle cells.  Within cells, the 
non-muscle isoforms have multiple functions as constituents of focal adhesions, adherens 
junctions, stress fibers, hemidesmosomes, neuronal synapses, glomerular podocytes, and 
contact sites of lymphocytes (Otey and Carpen, 2004).  More specifically, actinin-1 localizes 
to the inner surfaces of cells, playing a role in adhesion plaques and cell junctions, while 
actinin-4 plays a more active role in actin bundling and motility, as it is concentrated at the 
leading edge of motile cells (Yamamoto et al., 2007) and in membrane ruffles (Menez et al., 
2004).  Fascin, which had been mentioned previously as a bundling protein, can also act as a 
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cross-linking protein and aids in the formation of orthogonal networks of actin filaments 
(Kureishy et al., 2002).  Aside from these two well-known cross-linkers, about 23 other 
classes of proteins have been identified which can crosslink actin into tight or loose bundles 
and meshworks (Kries and Vale, 1999).  These proteins, therefore, are important for 
organizing actin into arrays that can aid in motility, contractility, or adhesion. 
 
Contractility and Actin-Binding Proteins 
 Although motility, adhesion, and the regulation of these functions are extremely 
important aspects of actin cytoskeleton function, for the purposes of this document, the focus 
will be narrowed more specifically toward the contractility function of actin arrays, and how 
this is regulated by various pathways and actin-binding proteins.   
 Contractility in cells is thought to be essential for tail retraction in the lamella of 
migrating cells (Pellegrin and Mellor, 2007), as well as in many other processes.  Fibroblasts 
migrating into wounds become activated and differentiate into specialized myofibroblasts, a 
phenotype that confers a two-fold increase in contractility (B. Hinz, 2007) in the cells.  This 
enhanced contractility serves to remodel the extracellular matrix to align collagen fibers in 
order to close a wound (Gabbiani et al., 1971).  In addition to the myofibroblasts involved in 
wound healing, the epithelial cells in the vicinity of a wound also become increasingly 
contractile.  In these cells, this allows for assembly of actomyosin cables at the wound edge, 
linked to adjacent cells and subsequently causing a “pursestring” closure of the gap through 
contractile activity (Bement et al., 1993).  This same contractile process is also used for 
closure of epithelial sheets in embryogenesis, and also in other aspects of development; 
embryonic branching of the lungs is regulated by the same GTPases that are responsible for 
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the generation of intracellular tension (Moore et al., 2002).  Even before development of an 
embryo, actin cytoskeleton contractility seems to be important for very early remodeling of 
the cytoskeleton following fertilization in animal oocytes (Stack et al., 2006). Additionally, 
many other cell types in the body exhibit contractile activity linked to function; the 
myoepithelial cells which surround the ducts of exocrine glands have contractile actin 
structures (Pellegrin and Mellor, 2007) and in the vasculature, changes in the pressure and 
flow of blood cause an increase in contractile structures in vascular smooth muscle cells in 
order to remodel the surrounding matrix and potentially shield other cells from the 
consequences of increased strain (Humphrey, 2008).   
 The subcellular structures that are primarily responsible for cellular contractility are 
the stress fibers, which are bundles of between 10 and 30 actin filaments held together by 
crosslinking proteins (Cramer et al., 1997), and anchored by focal adhesions.  These bundles 
of filaments are often anti-parallel or have an even less orderly arrangement, with the ends 
being of the same polarity but the inside of the fiber being mixed, a characteristic known as 
“graded polarity” (Cramer et al., 1997).  Interactions with myosin II are essential for stress 
fiber function, as this motor molecule is the backbone of contractile activity in non-muscle 
cells.  Myosin II and α-actinin are arranged in alternate bands along the length of stress fibers 
(Langanger et al., 1986), and the tails of myosin II are able to bind adjacent actin filaments; 
as this plus-end motor moves along, it pulls the adjacent and oppositely polarized filaments 
in opposite directions, which generates contractile force.    
 There are several types of stress fibers: dorsal, ventral, and transverse (Small et al., 
1998) and stress fibers in different locations possess distinct features.  Dorsal fibers are 
associated with focal adhesions at one end of the fiber, and are shorter in length compared to 
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ventral stress fibers (Pellegrin and Mellor, 2007). Ventral stress fibers are anchored by focal 
adhesions at both ends of the bundle (Burridge, 1986) and are composed of the end-to-end 
joining of two dorsal stress fibers (Hotulainen and Lappalainen, 2006).  Finally, transverse 
stress fibers are not associated with focal adhesions, and appear to consist of an end-to-end 
joining of short actin bundles (Hotulainen and Lappalainen, 2006).  The attachment to focal 
adhesions is central to the strength these stress fibers can generate, as the force applied on the 
fibers by the adhesions allows for cell retraction during motility, and in turn, the tension 
generated by the stress fibers augments the growth of focal adhesions which are sensitive to 
mechanical strain (Le Clainche and Carlier, 2008).  The relationship between focal adhesions 
and stress fibers requires an exquisite balance, however, as it is easy to see how extremely 
strong adhesions would inhibit contraction, while focal adhesions which have only a loose 
attachment to substrate would also inhibit contraction for lack of a tensional force. 
 The formation of stress fibers is regulated by the activities of the Rho GTPase family 
of proteins.  The Rho family proteins have been implicated in the regulation of many 
different actin arrays; Rac activity is associated with lamellipodia formation, Cdc42 with 
filopodia, and Rho with stress fibers and adhesion (Papakonstanti and Stournaras, 2008).  
Rho GTPases can regulate assembly of contractile arrays in various “activity zones” (Bement 
et al., 2006) that are spatially constrained and distinguished by high levels of Rho activity 
which lasts for a short duration, usually minutes.  An example of such a zone would be at 
wound borders, where actin-myosin arrays are highly prevalent.  There are three Rho 
GTPases which can stimulate formation of stress fibers, RhoA, RhoB, and RhoC (Giry et al., 
1995), but RhoA is the major regulator in this process (Pellegrin and Mellor, 2007).  
Activated RhoA activates the serine/threonine kinase ROCK, which in turn phosphorylates 
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and activates the myosin light chain 2 at serine 19; ROCK also inhibits myosin phosphatase 
(MYPT) to prevent dephosphorylation of the myosin light chain.  Phosphorylation of 
myosin’s light chain allows the motor to “walk” along filaments, thus enhancing 
contractility.  This pathway also initiates stress fiber formation (Le Clainche and Carlier, 
2008), as the activity of RhoA increases overall tension in the cell and in focal adhesions, and 
stress fibers form in response to the increased stiffness.  Additionally, mDia, a formin protein 
mentioned previously as being important for cell migration, is an actin nucleator that is 
another important effector downstream of RhoA activation and seems to be important for 
dorsal stress fiber formation, but not required (Hotulainen and Lappalainen, 2006).  ROCK 
activity appears to be necessary for global contraction in a 3D matrix model in response to 
growth factors (Tamariz and Grinnell, 2002), which indicates that its activity in increasing 
cortical tension and causing stress fiber formation increases contractility on a large scale. 
Aside from the aforementioned functions, highly contractile cells may be important 
for remodeling the extracellular matrix in a way that promotes invasion of cells.  Since 
adhesions are also essential for movement, and adhesions control the formation and 
regulation of stress fibers, the stiffness of the substrate is important for movement.  
Adhesions are the mechanosensors of a cell, and with a soft substrate, formation of dynamic 
adhesions would be difficult for a migrating cell.  In a microenvironment where surrounding 
cells are highly contractile and have created a stiffened extracellular matrix, migration by 
other cells would be much more efficient; focal adhesions could form and the necessary 
contractility for propelled forward movement would be achieved as a result.  Thus, enhanced 
contractility in surrounding cells would be ideal for a highly migratory cell such as a tumor 
cell attempting to extravasate the tissue into a blood vessel.  
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Palladin and the Actin Cytoskeleton 
 Palladin is a phosphoprotein discovered independently but almost simultaneously by 
the Otey lab (Parast and Otey, 2000) and the Carpen lab in Finland (Mykkänen et al., 2001a).  
The Otey lab identified palladin through close examination of an antibody originally thought 
to be against α-actinin, but revealed to be made against a novel protein that colocalized with 
α-actinin and was tightly associated with the actin cytoskeleton (Parast and Otey, 2000).  
Many studies have shown that palladin is a unique protein that can directly bind actin and 
cross-link actin filaments (Dixon et al., 2008), but can also bind many other proteins such as 
ezrin (Mykkänen et al., 2001b), Lasp-1 (Rachlin and Otey, 2006), Eps8 (Goicoechea et al., 
2006), profilin (Boukhelifa et al., 2006), Ena/VASP family members (Boukhelifa et al., 
2004), ArgBP2 (Rönty et al., 2005), Src and SPIN90 (Rönty et al., 2007), LPP (Jin et al., 
2007), and α-actinin (Rönty et al., 2004).  The multitude of binding partners, particularly 
those proteins which bind actin themselves, such as profilin, α-actinin, ezrin, Eps8, Lasp-1, 
and Ena/Vasp provide hints that palladin may also be acting as a scaffolding protein in cells.  
Scaffolding proteins serve to spatially and temporally organize intracellular pathways into 
functional signaling modules (Marinissen and Gutkind, 2005); thus, palladin may have many 
roles within cells. 
 A single gene encodes palladin but gives rise to several isoforms due to the presence 
of alternative transcriptional start sites along the length of the gene (Rachlin and Otey, 2006).  
There are three major isoforms of palladin, with molecular weights of 200kD, 140kD, and 
90kD.  These isoforms are well-characterized and have been exhaustively examined, but 
recent data from transcriptome databases indicates that there may be as many as seven 
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palladin isoforms in humans, and little is known about the function of the four newly-
identified isoforms.  The three classical isoforms are expressed across vertebrate species, and 
all have different expression patterns.  The 200kD isoform is restricted to heart and bone 
(Rachlin and Otey, 2006); the 140kD isoform is widely expressed in developing organs, but 
is restricted to smooth muscle in adult animals, and the 90kD isoform is ubiquitously 
expressed in embryonic animals, but is downregulated in many adult organs (Rachlin and 
Otey, 2006).  Palladin knockout mice have severe defects in development and display an 
embryonic lethal phenotype, with herniations of the liver and intestine and a failure to close 
the neural tube (Luo et al., 2005). Relevant to the current study is the existence of a 115kD 
isoform of palladin that was found to be expressed only in HeLa cells (Parast and Otey, 
2000), and an isoform of 75kD that is restricted to expression in human fibroblasts associated 
with tumors (Salaria et al., 2007).  These two isoforms have not yet been studied in great 
detail.  Thus, much is known about the expression of several of the palladin isoforms, but the 
functions of palladin and its isoforms are still being explored. 
 On a cellular level, palladin is localized primarily to stress fibers, co-localizing with 
α-actinin in a punctate pattern along the length of the bundled filaments (Parast and Otey, 
2000).  Additionally, palladin has been found in focal adhesions (Parast and Otey, 2000), 
neurite outgrowths and growth cones (Boukhelifa et al., 2001), membrane ruffles and 
podosomes (Goicoechea et al., 2006), at the leading edge of cells along a wound edge in 
astrocytes (Boukhelifa et al., 2003), and in wound granulation tissue (Rönty et al., 2006), 
emphasizing its role in actin-based structures in cells.  Knocking down palladin results in a 
loss of stress fibers and focal adhesions (Parast and Otey, 2000), and a decrease in 
podosomes and membrane ruffles (Goicoechea et al., 2006), which shows that palladin is not 
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only localized to, but actually required for many of these actin structures.  Furthermore, 
overexpressing either the 90kD or 140kD isoforms of palladin in COS-7 cells causes 
excessive bundling of actin filaments into large, long bundles or stellate bundles, respectively 
(Rachlin and Otey, 2006).  Thus, palladin seems to be essential for organizing actin into 
arrays that could play a part in contractility, motility, and adhesion.  Additionally, binding to 
its partners that are known scaffolds adds another level of importance to the function of 
palladin in organizing actin arrays.  
 
Palladin Binding Partners 
Palladin is a member of a protein family with myotilin and myopalladin, which are 
found to be expressed in striated muscle.  Within striated muscle these two proteins are 
localized to Z-discs, an area known to be important for sarcomere organization (Otey and 
Carpen, 2004). They also bind to α-actinin within the sarcomere.  Palladin, which shares 
functional IgC2 domains with myotilin and myopalladin, localizes to the Z-lines of 
embryonic cardiac myocytes (Parast and Otey, 2000) and also to the dense region of stress 
fibers, a region which is considered to be the non-muscle equivalent of Z-disks in muscle 
cells.  The Ig domains of palladin are found in the three canonical palladin isoforms, and 
these domains traditionally are known to be present in both intracellular and extracellular 
proteins, playing a role in protein-protein interactions (Dixon et al., 2008).  Ig domains are 
quite common in proteins that are associated with actin and myosin, and particularly in those 
proteins expressed in striated muscle, like titin and myomesin; therefore, Ig domains are 
linked to the construction of a very organized cytoskeleton (Dixon et al., 2008).  Palladin has 
three Ig domains in the 90kD isoform, four in the 140kD isoform, and five in the 200kD 
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isoform (Rachlin and Otey, 2006), but it is the third Ig domain (Ig3) that is the minimum 
fragment that is able to bind to actin (Dixon et al., 2008).  The 90kD isoform can also 
crosslink actin in co-sedimentation assays (Dixon et al., 2008), showing that this binding to 
actin has a function. 
Aside from the Ig domains, the two polyproline domains of palladin are very 
significant in terms of function.  Proline-rich domains are motifs that contain a minimum of 
five consecutive prolines and lack bulky side chains (Boukhelifa et al., 2006). VASP binds to 
palladin at its N-terminus proline-rich domain (Boukhelifa et al., 2004), and the two 
colocalize in stress fibers.  The VASP family of proteins, mentioned earlier, is very important 
for cell migration.  They tend to localize to sites of actin polymerization, such as at the 
leading edge of migrating cells and in focal adhesions, and also serve to stabilize actin 
filaments and form bundles (Boukhelifa et al., 2004).  Profilin also binds palladin in a highly 
dynamic interaction at the second proline-rich domain (Boukhelifa et al., 2006); profilin also 
binds VASP, which can also function to recruit profilin in cells, suggesting that VASP and 
palladin may work together to recruit profilin to sites of actin polymerization.  Palladin is 
able to bind profilin in the absence of VASP (Boukhelifa et al., 2006), which means that 
palladin could possibly be part of other protein complexes that regulate profilin activity.   
Src also binds palladin’s polyproline region (Rönty et al., 2007); Src is a non-receptor 
tyrosine kinase that, upon activation, is found at the plasma membrane where it serves to 
reorganize the cytoskeleton and interact with many other cytoskeletal proteins like Focal 
Adhesion Kinase (FAK), cortactin, and ezrin (Rönty et al., 2007); all of these actions result 
in formation of lamellipodia and membrane ruffles.  Palladin is known to be localized to 
membrane ruffles, and when it is knocked down, the number of ruffles is reduced, which 
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implies that the interaction of palladin at Src’s SH3 domain plays a part in the formation of 
membrane ruffles (Rönty et al., 2007).   
Lasp-1 localizes to points of actin assembly, such as focal adhesions, focal contacts (a 
different type of actin-based cell adhesion), lamellipodia, membrane ruffles, and pseudopodia 
(Grunewald and Butt, 2008), linking it to motility.  The LIM domain of the protein mediates 
protein-protein interactions, and Lasp-1 is known to affect positioning of zyxin, another 
cytoskeletal protein in focal adhesions (Grunewald et al., 2007); also, the actin-binding 
domain of Lasp-1 allows for a direct association with actin membrane extensions in the cell.  
Lasp-1 is also found in stress fibers, which, as mentioned previously, are important for 
contractility and possibly migration.  This protein also interacts with the proline-rich domain 
of palladin (Rachlin and Otey, 2006), which further implicates palladin in a range of 
activities within cells. Eps8, a protein identified to be a substrate for the EGF receptor, is also 
a substrate for other receptor and non-receptor tyrosine kinases (Chen et al., 2008).  It also 
serves as a Rac-GEF in a complex with Sos-1, Abi-1 and palladin to activate Rac, a member 
of the Rho-family GTPases. Additionally, Eps8 rearranges the actin cytoskeleton through 
interactions with actin-binding proteins like Arp2/3 and WAVE/WASP (Goicoechea et al., 
2006; Welsch et al., 2007).   Palladin binds Eps8 at one of the proline rich domains as well, 
and the two colocalize at membrane ruffles after treatment with growth factors (Goicoechea 
et al., 2006). 
Hence, the Ig domains and the proline rich domains of palladin play a very important 
part in regulation and organization of the actin cytoskeleton through their multiple binding 
partners.  Other binding partners like ezrin and α-actinin bind different parts of palladin, and 
 16 
the importance of these interactions is becoming increasingly evident, but the aforementioned 
domains are clearly very important for palladin’s function within cells. 
 
Palladin Function 
 As stated previously, within cell culture models, palladin is localized to many actin-
based structures within cells, and appears to be important for stress fiber formation, 
membrane ruffles, cell adhesions, and motility.  In a knockout mouse model, an absence of 
palladin leads to severe defects in neural tube closure and herniations in the body wall (Luo 
et al., 2005), which links palladin to roles in motility and possibly contractility in 
development.  Palladin is also upregulated in differentiating monocytes (Mykkänen et al., 
2001b), Rcho-1 cells differentiating into trophoblast cells (Parast and Otey, 2000), and in 
mesenchymal cells subjected to tensile strain in order to differentiate into osteogenic cells 
(Wall et al., 2007).  All of these changes require large-scale reorganizations of the 
cytoskeleton.  In a wound-healing model of astrocytes, palladin localizes to the leading edge 
of the wound (Boukhelifa et al., 2003). In other systems, palladin is found in wound 
granulation tissue and is upregulated very early in the process by which fibroblasts in the 
vicinity of a wound become activated in the presence of factors such as TGFβ1 and 
differentiate into myofibroblasts (Rönty et al., 2006).  These myofibroblasts are highly 
secretory, contractile, and motile, and contribute to the closure of a wound.  The presence of 
palladin in contractile stress fibers, and its role in other types of motile cells, suggests that 
palladin could be an integral contributor to the myofibroblast phenotype. 
 Interestingly, palladin’s role in wound healing tissue may extend to a disease 
phenotype.  Recently, much focus has been placed on the increasing evidence that the 
 17 
molecular programs initiated in the wound healing response are very similar or the same as 
those initiated in the microenvironment of a tumor.  Upon injury in a tissue, the blood 
coagulation cascade concomitantly sets off a signaling cascade that recruits inflammatory 
cells, stimulates proliferation of multiple cell types including fibroblasts, and allows for 
directed cell migration (Chang et al., 2004).  A chronic inflammatory state in tissues has long 
been known to be a risk factor for development of cancer; chronic pancreatitis is a major risk 
factor for pancreatic adenocarcinoma (Chu et al., 2007), cirrhosis of the liver is a risk factor 
for liver cancer, and stomach ulcers are associated with an increased risk of gastric cancer 
(Chang et al., 2004).  The connection between the two states has not been completely 
established, but it seems logical that the persistence of a cellular response involving 
continued growth, secretion of inflammatory factors, and secretion of metalloproteinases 
could become misregulated and promote the formation, growth, and invasion of a tumor.  
Accordingly, tumors have been referred to as “wounds that do not heal” (Dvorak, 1986) for 
the persistent appearance of a wound-healing environment in the area surrounding the tumor. 
  Gene array studies in fibroblasts exposed to serum, the soluble fraction of coagulated 
blood, uncovered a series of genes upregulated known as the “core serum response” or CSR 
(Chang et al., 2004).  These genes had functions ranging from progression through the cell 
cycle to remodeling of the extracellular matrix and acquisition of a myofibroblast phenotype.  
When examining various tumor types, Chang and colleagues found that CSR signature was 
not found in all tumors, indicating a possible “wound healing phenotype.”  Tumors that 
expressed the CSR signature had an increased risk of metastasis, and the presence of the CSR 
signature was not easily extinguished from the tumor in spite of surgical intervention (Chang 
et al., 2004).   
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 Platelets express TGFβ1 in a tissue injury setting (Bissell and Radisky, 2001), and 
TGFβ1 upregulates palladin early on in the acquisition of the myofibroblast phenotype in 
wound healing (Rönty et al., 2006), a phenotype mentioned above as resulting from the CSR 
signature.  Also, palladin is upregulated in a glial injury model (Boukhelifa et al., 2003).  
Therefore, it is logical to ask if palladin may be important in establishing a wound-healing 
microenvironment which promotes tumor growth and metastasis in cancer.   
 
The Cytoskeleton and Cancer 
 Multiple cytoskeletal proteins have been implicated in cancer development and 
progression.  The majority of these proteins are important for the motility and contractility of 
cells that accompanies metastasis and invasion. 
 For example, Lasp-1 is a cytoskeleton protein mentioned earlier for its palladin 
binding, and it was originally identified from a cDNA library obtained from metastatic 
axillary lymph nodes from breast cancer, and it is overexpressed in 8-12% of human breast 
cancers (Lin et al., 2004).  Lasp-1 was also recognized in microarray studies examining 
genes associated with tumor development and cancer progression (Grunewald and Butt, 
2008).  At this point, the exact function of Lasp-1 is unknown; it does participate in neuronal 
differentiation and seems to be important for the migration and proliferation of cancer cells 
(Grunewald and Butt, 2008), as knocking it down by siRNA leads to an inhibition of 
migration and proliferation (Grunewald et al., 2006), but otherwise, the roles for this protein 
have not been defined.  The localization of Lasp-1 to stress fibers is mediated by palladin, 
which binds to the SH3 domain of Lasp-1 and recruits it to stress fibers (Rachlin and Otey, 
2006).  Interestingly, besides stress fiber and other actin structure localization, Lasp-1 can 
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also be found in the nucleus and when knocked down, it leads to cell cycle arrest at G2 
phase, suggesting it may have functions as a transcriptional regulator (Grunewald et al., 
2006).  At this point, most work on Lasp-1 has been done in breast or ovarian cancer models, 
but due to its general role in cell motility and contractility, it may be important in the 
progression of other cancer types as well. 
Like Lasp-1, profilin-1 has also been implicated in gene regulation, playing a role in 
mRNA splicing and gene transcription.  Interestingly, profilin-1 is downregulated in breast 
cancer, pancreatic cancer, and hepatic cancer (Zou et al., 2007), which is counterintuitive for 
a protein which seems to be a promoter of actin polymerization under most conditions.  But, 
in fact, suppressing the expression of profilin-1 leads to a 40% increase in motility of the 
breast cancer cell line MDA-MB-231 (Zou et al., 2007), and exogenously expressing 
profilin-1 in breast cancer cells expressing low levels of the protein seems to suppress their 
tumorgenicity (Janke et al., 2000).  There is evidence to suggest that profilin-1, then, is 
actually a tumor suppressor.  Accordingly, there are theories as to how this could be the case 
with a protein that binds free G-actin; perhaps low levels of profilin-1 increases the levels of 
free G-actin to be used in actin-treadmilling, or decreases the amount of cell-cell and cell-
matrix adhesions (Zou et al., 2007), which could allow cells to detach more easily from the 
surrounding matrix and disseminate to other tissues.  The actin-binding domain of profilin-1 
is essential for the protein to display its tumor suppressor function (Wittenmayer et al., 
2004), which means that low profilin-1 is more than likely playing a direct role in actin 
dynamics as opposed to an effect mediated through altered interactions with its known 
binding partners. 
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 Cofilin is also emerging as an important player in the determination of the invasive 
phenotype of cancer cells. Cofilin is able to bind both F-actin and G-actin, and as mentioned 
earlier, is considered to be an actin depolymerizer.  The entire cofilin pathway plays a role in 
the early steps of the motility process, and these early steps of defining the direction for 
migration and formation of cell protrusions is vital in tumor cells attempting to migrate out of 
a primary tumor.  Not surprisingly, cofilin is reported as being highly expressed in many 
cancers, including drug resistant pancreatic cancer cell lines, renal tumors, ovarian cancer, 
human lung cancer cells undergoing EMT, oral squamous cell carcinoma and invasive rat 
and human mammary carcinomas (Wang et al., 2007).  However, it is important to note that 
overexpression in tumor cells can actually inhibit motility and invasion, so although it may 
be highly expressed in many cancers, this alone is not necessarily an indicator of 
aggressiveness.  In fact, new evidence shows that other members of the cofilin pathway are 
equally important in tumor cell motility.  LIMK1, a protein in the pathway which inactivates 
cofilin through phosphorylation, has also been associated with an invasive phenotype in 
prostate cancer cells when overexpressed, but as is the same with cofilin, the migration of 
individual cells decreases when LIMK1 is overexpressed, implying that it may be important 
for directed motility (Ahmed et al., 2008).  Thus, it is likely that it is not just cofilin, but also 
the regulators of cofilin, that are important in cancer cell invasion and motility (Wang et al., 
2007). 
 Eps8 localizes to highly dynamic actin-based membrane dorsal ruffles (Goicoechea et 
al., 2006) with palladin and has also been seen to localize to the tips of actin filaments, 
filopodia, and at the leading edge of migrating cells (Welsch et al., 2007).  When Eps8 is 
knocked down, protrusion formation and assembly of cell-cell junctions are impaired, and 
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cell shape is also altered (Welsch et al., 2007).  Also, Eps8 binds IRSp53, an adaptor protein 
which is linked to Rho-family GTPases (Maa et al., 2007).  Eps8 can modulate the activity of 
Src (Chen et al., 2008), and has been categorized as an actin filament capping protein (Maa et 
al., 2007).  These data further implicate Eps8 as being an important regulator of the actin 
cytoskeleton.  Eps8 expression has been examined in cervical cancer (Chen et al., 2008), 
colorectal cancer (Maa et al., 2007), thyroid cancer (Griffith et al., 2006) and pancreatic 
cancer (Welsch et al., 2007) in detail.  In cervical cancer, Eps8 staining was increased in 
tumor compared to noncancerous tissue, and high Eps8 staining was associated with poor 
survival and increased invasion (Chen et al., 2008).  Even more interestingly, decreasing 
Eps8 in HeLa and siHA (a model cell line for cervical cancer) cells sensitized these cell lines 
to chemotherapeutics (Chen et al., 2008).   A study involving colorectal cancer found that 
Eps8 is increased in advanced stages of disease, and cell lines that were considered high Eps8 
expressors grew more quickly than low level expressors (Maa et al., 2007).  Additionally, 
Eps8 was implicated as having a possible interaction with focal adhesion kinase (FAK).  
Eps8 elevates activity of Src in colon cancer cell lines, and also increases serum-dependent 
activity of FAK. Activated FAK mediates binding of Src family tyrosine kinases (Maa et al., 
2007), showing that Eps8 activity and FAK activity are connected, probably through Src 
activation.  FAK is overexpressed in many cancers, and acts to transmit signals which 
regulate proliferation, migration, and adhesion (Lightfoot et al., 2004), making a connection 
between Eps8 and FAK very important in terms of cancer cell motility.  In the study 
involving pancreatic cancer, Eps8 expression increased depending on the source of the 
pancreatic cancer cell line.  For example, Panc-1, a cell line derived from a primary 
pancreatic tumor, had lower levels of Eps8 than AsPC-1, a cell line derived from the highly 
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metastatic cells of ascites fluid (Welsch et al., 2007).  This data also correlates with the 
increase in migratory potential seen in these cell lines.  Although Eps8 expression is several-
fold higher in pancreatic ductal adenocarcinoma by protein detection, immunohistological 
analysis paints a much cloudier picture.  In tissue sections, Eps8 labels neoplastic cells of a 
pancreatic tumor, but at levels indistinguishable from normal ductal cells (Welsch et al., 
2007), showing a disconnect between the protein expression in cell lines and expression in 
sections of actual tumor.  This could be due to genetic differences in cell lines or simply the 
effect of culturing cells on plastic in an ex vivo environment, as substrate stiffness can have a 
significant impact on the expression of cytoskeletal proteins.  As a result, the function of 
Eps8 in actual pancreatic tumors remains to be determined, but it clearly has a role in actin 
dynamics in multiple cell and tumor types.  
 For some time now α-actinin, the ubiquitous cross-linking and bundling protein, has 
been linked to cancer, but the precise contribution has yet to de described or characterized.  
Initial studies indicated that a decrease in α-actinin increased motility in 3T3 cells, and α-
actinin deficient cells injected into nude mice formed tumors (Glück and Ben-Ze'ev, 1994).  
Examination of the two non-muscle isoforms actinins 1 and 4 reveals that despite high 
sequence homology, they are implicated in different cancers.  Actinin-1, which localizes to 
stress fibers and focal adhesions, is found to be overexpressed in sarcomas (Suehara et al., 
2006) and has been implicated in invasive motility of lymphocytes (Stanley et al., 2007).  
Actinin-4, however, has been linked to breast, ovarian, pancreatic, colorectal, lung and 
esophageal cancers (Hatakeyama et al., 2006; Honda et al., 1998; Honda et al., 2005; Kikuchi 
et al., 2008; Yamamoto et al., 2007).  In cells actinin-4 has been linked to actin bundling and 
cross-linking and also motility.  Actinins 1 and 4 are also scaffolding proteins (Otey and 
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Carpen, 2004), and misregulation of the pathways organized by scaffolding proteins can also 
lead to tumorigenesis.    
  What is striking about the actinin studies to date is the lack of focus on actinin-1.  
Due to its function at cell adhesions, it appears as though it would be equally important to 
study this isoform in cancer, where the dynamics of focal adhesions are important; however, 
it is virtually ignored in the literature.  This may be because the high sequence similarity of 
the two isoforms suggests functional similarity; however, their different localization patterns 
indicate that there are likely distinct functional differences between the two isoforms. 
 
Palladin and Cancer 
 Although multiple actin-associated proteins have been implicated in cancer, palladin 
had only been studied and characterized in development and wound-healing, and was not 
suspected to play a role in cancer.  The palladin field changed in response to a 
comprehensive, ten year study of a large family in Washington State, known as Family X.  
This family suffers from a very high incidence of pancreatic cancer.  Cancer resulting from 
an inherited susceptibility accounts for about 10% of all cases of pancreatic adenocarcinoma, 
a uniformly lethal disease.  The leader of this study, Teri Brentnall, embarked on a search to 
find the gene responsible for the susceptibility to pancreatic cancer.  Through the use of gene 
arrays and sequencing techniques, palladin was the gene identified as being mutated in all of 
the afflicted members of Family X (Pogue-Geile et al., 2006).  The palladin gene in the 
affected family members carries a single amino acid substitution from a proline to a serine at 
position 239, which is in the binding region for α-actinin.  Due to the differences between a 
hydrophobic amino acid like proline and a hydrophilic amino acid like serine, this could have 
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a dramatic impact on the interaction between palladin and α-actinin in vivo.  Transfecting the 
mutated palladin into HeLa cells resulted in significant changes in the actin cytoskeleton and 
an increase in motility (Pogue-Geile et al., 2006).  Palladin was also overexpressed very early 
in disease progression in both sporadic and in the familial form of pancreatic cancer (Pogue-
Geile et al., 2006). 
 This study was surprising, as there are currently no other cytoskeletal proteins that 
have been implicated so directly in the development of a tumor.  In the previous section 
many studies were noted that examined overexpression of cytoskeleton proteins, but none 
had been linked to the formation of a cancer with just a single mutation.  However, this study 
looked at palladin in the context of tumor cells, and earlier palladin was referred to in the 
wound healing environment present in cancer, a subset of cells that does not include tumor 
cells.  In 2007, Salaria and colleagues released a study where they examined sections of 
sporadic pancreatic tumors, which make up the other 90% of cases of adenocarcinoma, by 
immunohistochemistry.   They found that palladin was overexpressed in about 96% of these 
tumors, but in the non-neoplastic stroma, and not the tumor cells (Salaria et al., 2007).  
Western blot analysis indicated that palladin levels in pancreatic cancer cell lines were 
similar to control lines, and that the overexpression was limited to cancer-associated 
fibroblasts (Salaria et al., 2007).   
 So, clearly palladin is playing some role in pancreatic cancer, but the exact 
contribution to development or invasion is unclear.  Many questions remain.  Is palladin 
being overexpressed in the tumor cells or in the non-neoplastic stroma?  What is the function 
of palladin in tumor progression?  An involvement in a cancer such as pancreatic 
adenocarcinoma is especially interesting because this cancer is known to be extremely 
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difficult to detect, with very rapid metastasis and high fatality.  Given that a single palladin 
mutation can result in pancreatic tumor formation, it is worth intense investigation to see how 
palladin contributes to the lethality of the disease. 
Pancreatic Cancer 
 
Pancreatic adenocarcinoma, a cancer arising from the ductal cells of the exocrine 
pancreas, is a uniformly lethal disease that affects about 30,000 people a year; it is also the 
fourth leading cause of cancer death in the United States (2007) despite its relatively low 
prevalence.  Recently, the death rates of many other cancers have decreased due to advances 
in early detection, risk factor maintenance, and treatment options, while pancreatic cancer 
continues to hold a dismal survival rate of just 5% over one year.   
One of the difficulties with pancreatic cancer is that most patients are diagnosed with 
metastatic disease, which carries a survival rate of three to six months.  The majority of 
cancers are much more slow-growing and diagnosis occurs at earlier stages.  As a result, 
many questions about pancreatic cancer need to be answered.  Is the problem a result of a 
failure to diagnose the disease at an early, treatable stage?  Are pancreatic tumors inherently 
more aggressive than other epithelial cancers?  If the underlying problem is a failure of early 
detection, then it is essential to improve screening techniques, but if the problem is a 
difference in mechanism, then the focus needs to lie on examining what makes pancreatic 
cancer so different.  Both issues will not be easy to tackle given the lack of patients available 
to study early stage disease.  Also, there are no clear cut ways to separate out which 
populations are at risk for pancreatic cancer in order to study them. 
   There are multiple risk factors for pancreatic adenocarcinoma, including smoking, 
age, alcohol consumption, history of chronic pancreatitis, and family history; however, none 
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of these have been linked to pancreatic cancer with any exclusivity.  Accordingly, detecting 
people who are most at risk for the disease is difficult and time-consuming.  Moreover, 
screening individuals known to have a family history or an increased risk is challenging, as 
the pancreas is fairly inaccessible by simple palpation and imaging techniques.  The fact that 
the pancreas expresses enzymes also presents an issue, since it often auto-digests during 
analysis.  So although earlier detection is essential, a lack of concrete risk factors and good 
screening techniques makes this problem seemingly insurmountable. 
Since patients diagnosed often already have metastases, it has been nearly impossible 
to study the etiology of this lethal disease. Therefore, at this point, it is essential to study the 
underlying mechanism of pancreatic cancer, because its rapid metastasis and resistance to 
treatment have shown it may be different from other cancers.  Looking at some of the unique 
features of pancreatic adenocarcinoma, such as the presence of desmoplasia, is proving to be 
extremely important in terms understanding the deadly characteristics of the disease. 
 
Desmoplasia and Pancreatic Cancer 
 One distinguishing characteristic of pancreatic adenocarcinoma is the excess of 
fibrotic tissue and altered extracellular matrix surrounding the tumor which aids in its growth 
and metastasis (Mahadevan and Von Hoff, 2007).  This change in the stroma is known as 
“desmoplasia,” and although it has been observed in other cancers, it is a hallmark of 
pancreatic cancer. There are many cell types that inhabit the desmoplastic stroma of a tumor, 
including mesenchymal cells, vascular cells, and inflammatory and immune cells (Chu et al., 
2007).  It is important to note that the components of this reactive stroma are similar to those 
found in the wound healing response, further strengthening the argument that a tumor can be 
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considered a “wound that never heals.” (Chu et al., 2007).   It is not entirely clear whether 
this reaction is a protective mechanism by the host to contain a tumor or if it is actually 
beneficial for the tumor (Löhr et al., 2001).  Evidence seems to point to the idea that the 
desmoplastic reaction is actually advantageous to the tumor, and even more intriguingly, may 
promote initial carcinogenesis.  For example, submandibular gland epithelial cells 
transformed with polyoma virus require salivary gland mesenchyme to grow (Bhowmick et 
al., 2004; Derynck and Akhurst, 2007).  In addition, a recent study showed that in a co-
culture system, stromal fibroblasts function to “lead” cancer cells out of the tumor 
environment to metastasize (Gaggioli et al., 2007).  Also, the cells of the reactive stroma can 
secrete growth and pro-angiogenic factors to tumor cells in a paracrine fashion (Chu et al., 
2007; Kalluri and Zeisberg, 2006; Kopfstein and Christofori, 2006).  Additionally, mammary 
epithelial cells that have been transplanted into fat pads containing irradiated fibroblasts have 
an increased incidence of becoming tumorigenic compared to those implanted with non-
irradiated fibroblasts (Barcellos-Hoff and Ravani, 2000), and irradiated fibroblasts were able 
to increase the invasiveness of pancreatic cancer cells in vitro.  Finally, sections of pancreatic 
tumor with high stromal activity correlated with a worse prognosis compared to those with a 
low stromal reaction (Erkan et al., 2008).  So although it is unclear at this point just how 
much of a role the desmoplastic stroma is playing in tumor formation, progression, and 
eventually metastasis, it is an emerging field that could be key to understanding a disease as 
seemingly unique as pancreatic cancer. 
 
Fibroblasts and the Stroma 
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There are multiple mesenchymal cell types in reactive stroma, but of those, 
fibroblasts are the most abundant.  These non-vascular, non-epithelial (Kalluri and Zeisberg, 
2006) cells have multiple functions in the stroma.  Some of these include: deposition of 
extracellular matrix, which encompasses the synthesis of multiple collagen types, fibronectin, 
and laminin; regulation of epithelial differentiation; wound healing responses; and general 
maintenance of homeostasis of the surrounding epithelial cells by secretion of growth factors 
and direct cell-cell interactions (Kalluri and Zeisberg, 2006).  
During normal wound healing response, fibroblasts become activated.  This change 
occurs due to organizational and mechanical changes in the extracellular matrix and release 
of cytokines by nearby inflammatory cells (Arora et al., 1999; Gallucci et al., 2006; Meyer-
ter-Vehn et al., 2006; Sobral et al., 2007).  Activated fibroblasts acquire a myofibroblast 
phenotype, which makes them highly contractile, motile, and secretory.  This differentiation 
occurs over several steps, and requires a number of local events.  First, the fibroblast 
becomes more migratory through the development of contractile bundles of actin; 
cytoplasmic actins are utilized early on and the forces exerted by the actin bundles are quite 
small.  For this reason, the fibroblast is referred to as a “proto-myofibroblast” (B. Hinz, 
2007) during this stage.  The characteristics of fibroblasts at this stage of differentiation 
resemble those of cultured fibroblasts that have been activated due to the mechanical 
stimulation from the hard plastic substrate of the culture dish (B Hinz et al., 2007) .  As the 
stress on the extracellular matrix increases due to the changes in the fibroblasts, the proto-
myofibroblast further differentiates into a myofibroblast, a phenotype characterized by de 
novo expression of α-smooth muscle actin (α-SMA). Aside from stress on the extracellular 
matrix, the other events necessary for this final stage of transition to the myofibroblast are the 
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accrual of biologically active TGFβ1 and the expression of special extracellular matrix 
proteins such as the splice variant of fibronectin, ED-A FN (Dugina et al., 2001).   
Incorporation of α-SMA into stress fibers of the activated myofibroblast confers a higher 
contractile activity compared to α-SMA negative fibroblasts (B. Hinz, 2007).  Also present in 
these myofibroblasts are intracellular adherens or gap junctions, along with high numbers of 
cell-matrix attachment sites, known as supermature focal adhesions (B Hinz et al., 2007).  
These are distinct from classical focal adhesions in that they are longer and express vinculin, 
paxillin, tensin and specific integrins at higher levels (Dugina et al., 2001). The formation of 
these supermature focal adhesions is dependent both on incorporation of α-SMA into the 
actin bundles (B Hinz et al., 2003), and on the presence of a stiff matrix.  
In normal wound healing, this highly contractile activity of the myofibroblasts aids in 
efficient closure of dermal wounds, and once the wound has been sealed, these specialized 
fibroblasts undergo apoptosis.  In some pathological conditions, the myofibroblasts persist, 
resulting in continued ECM deposition and contractile activity (Rönty et al., 2006).   
Cirrhosis of the liver, glomerulosclerosis, and lung fibrosis are more common examples of 
diseases where this occurs, but most intriguingly, this persistence of activated fibroblasts has 
also been found to occur at the invasive front of neoplastic epithelial cells, and is considered 
the basis of the desmoplastic reaction in tumors.  For that reason, in the scenario of cancer, 
these fibroblasts are called “cancer-associated fibroblasts” (CAFs) or “tumor-associated 
fibroblasts” (TAFs). 
 
Tumor-Associated Fibroblasts in Cancer 
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Study of the tumor microenvironment is rapidly emerging.  For many years, the 
tumor cells themselves appeared to be the most important aspect of cancer to study, but it has 
become increasingly apparent that the stroma surrounding the tumor, and in particular, the 
tumor-associated fibroblasts, are playing a rather large part in the development and 
progression of tumors; in the previous section, it was noted that mutations in these cells could 
be causing initial carcinogenesis.  More specifically, the characteristics of myofibroblastic 
cells, such as the higher contractility, motility, and increased secretion, are likely all 
contributing to the disease. 
The enhanced motility of activated fibroblasts might connect to the tumor cells. In 
order for a tumor cell to metastasize, it must detach from the primary tumor, enter the stroma, 
intravasate into the lymph or circulatory system, and subsequently extravasate out to 
proliferate in a different tissue (Kopfstein and Christofori, 2006).  It is already well-
established that tumor-associated fibroblasts in the stroma secrete matrix metalloproteinases, 
and although there is evidence that tumor cells and the stroma can communicate through an 
intact basement membrane (Rønnov-Jessen et al., 1996), it seems more likely that the 
secretion of the matrix metalloproteinases degrades this basement membrane, which aids the 
tumor cells in invasion of the stroma.  As mentioned previously, it has been shown in a co-
culture system with squamous cell carcinoma and fibroblasts that along with the remodeling 
of the matrix provided by the fibroblasts and their secreted metalloproteinases, chains of 
carcinoma cells were observed to follow fibroblasts in tracks formed in the matrix (Gaggioli 
et al., 2007).  The two cell types needed to be in close proximity to occur, perhaps because 
the fibroblasts needed to remodel matrix close to the tumor cells so they could move through.  
Since it is not entirely known how tumor cells are able to invade the matrix and metastasize, 
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the idea that they could be following motile tumor-associated fibroblasts is very attractive.  
Moreover, we know that PDGF can stimulate fibroblasts grown in a 3D collagen matrix to 
migrate (Jiang et al., 2008), and colon cancers associated with a high degree of PDGF 
receptor expression by stromal cells have a higher metastatic potential (Kitadai et al., 2006).  
Additionally, the origin of the fibroblasts in metastases is unknown, and actual evidence that 
fibroblasts may be leading cancer cells out into the tissue could provide verification to the 
hypothesis that the fibroblasts are originating from the vicinity of the primary tumor.  
Apart from matrix metalloproteinases, the highly secretory tumor-associated 
fibroblasts also release extracellular matrix proteins, and growth factors such as HGF, VEGF, 
TGFβ1, EGF and FGF.  VEGF is well known as a pro-angiogenic factor, so it is clear that 
fibroblasts secreting VEGF are contributing to the formation of blood vessels to supply the 
tumor.  FGF, or fibroblast growth factor, is particularly interesting in the context of 
pancreatic cancer, as FGF-5 is found in both tumor-associated fibroblasts and tumor- 
associated macrophages, but is not expressed by normal fibroblasts in pancreatic tissue.  It 
has been found that two pancreatic cancer cell lines, Panc-1 and Mia-PaCa, use FGF receptor 
signaling, probably through FGF-5, to activate the MAP Kinase pathway, which is important 
for growth and proliferation (Powers et al., 2000).  TGFβ1 may be playing many roles in the 
tumor microenvironment, particularly when released by the tumor cells to activate 
fibroblasts, but fibroblasts secreting TGFβ1 may be causing tumor cells to produce more 
VEGF to further accelerate angiogenesis (Donovan et al., 1997), or in the case of pancreatic 
tumors, increasing invasiveness of the tumor cells by causing upregulation of matrix 
metalloproteinases (Ellenrieder et al., 2001).  HGF is another important growth factor that is 
expressed in PanIN lesions and the stroma of pancreatic adenocarcinoma, but is not present 
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in the epithelial cells of the cancer (Chu et al., 2007); in an in vivo setting, HGF promotes 
tumor cell motility, so fibroblasts are a likely source of this factor.  In a study involving 
human mammary epithelial cells forming ducts in mouse breast stroma, it was found that 
overexpression of HGF or TGFβ in the mouse fibroblasts induced the initiation of breast 
cancer with the normal human epithelial cells (Kuperwasser et al., 2004), lending further 
evidence to the hypothesis that fibroblasts may be the source of epithelial carcinogenesis, but 
on a more basic level, this study promotes the idea that excessive secretion of HGF and 
TGFβ by fibroblasts in the stroma can impact tumor growth and proliferation.  
Aside from the increase in secretion and motility seen in tumor-associated, activated 
fibroblasts, a substantial increase in contractility is also evident, which may also have 
implications in enhancing tumor growth and development.  As mentioned previously, 
contractility in activated fibroblasts in a wound healing environment promotes closure of the 
wound, and ceases once the wound has been sealed.  The role of contractility in a tumor 
environment is much different.  Contractility on behalf of the fibroblasts plays a part in 
stiffening the extracellular matrix, and the stiffness of the matrix is rapidly becoming an 
important aspect of tumor development and progression to study.   
It is already known that in the developing embryo, physical forces are essential for 
both regulation of developmental genes and the shaping of the embryo itself.  Although the 
coordinated movements of cells are partly responsible for this shaping, the mechanical 
properties of the responding tissue are equally important (Paszek and Weaver, 2004).   
Therefore, it is likely that in tumors, the mechanical properties of the surrounding tissue 
would generate an environment that is conducive to migration and perhaps invasion.  In fact, 
in breast cancer, tumor development appears to be correlated with an increase in mammary 
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gland tension which is connected to, among other things, an increase in stiffening of the 
extracellular matrix (Paszek and Weaver, 2004).  This stiffness may have many effects on 
both the tumor cells and the stromal fibroblasts.  It has been postulated that in the tumor 
cells, increased stiffness may alter cell adhesion contacts and signaling, activate 
mechanotransduction pathways, reorganize the cytoskeleton, or even modulate growth factor 
receptor expression and activity.  Even more intriguingly, a feedback loop may be 
established between the stroma and tumor cells that causes continuous and unchecked 
stiffening of the extracellular matrix.  A multitude of tumor cells growing within a gland that 
is still contained by a basement membrane will exert pressure on the quiescent stroma, and in 
the process, release factors like latent TGFβ1 in the ECM (Paszek and Weaver, 2004; Wipff 
et al., 2007); and in response, the fibroblasts will activate and exert a reciprocal force, 
cellularly generated, which equals the pressure applied by the tumor cells.  This is further 
countered by a resistance from the extracellular matrix which feeds back to further 
mechanically activate the stromal fibroblasts (Paszek and Weaver, 2004).  In order for the 
fibroblasts to generate this reciprocal force, they must be more contractile. 
The cytoskeleton appears to be the most sensitive component mechanosensing, in 
either the fibroblasts or the tumor cells.  This accounts for changes in contractility and 
migration seen in cells within mechanically altered environments.  In one 
mechanotransduction model, the cell is attached to an extracellular matrix protein by an 
interaction with a transmembrane protein, such as an integrin, and the integrin is in turn 
linked to the cytoskeleton by its intracellular domain linkage with an actin-binding protein 
like α-actinin (Janmey and Weitz, 2004).  Also, in some cell types such as osteoblasts, which 
are known to inhabit a hard matrix, changes in force result in differences in the transcription 
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of cytoskeletal proteins (Janmey and Weitz, 2004), like palladin (Wall et al., 2007), and there 
is evidence that in cancer, mechanical loading and tensional stress confer stress-dependent 
alterations in microtubule dynamics (Dennerll et al., 1988).  In myofibroblasts, 
mechanoperception is mediated by the cytoskeleton in the form of specialized focal 
adhesions called “fibronexi” in vivo and “supermature focal adhesions” in vitro, and the size 
of these adhesions is determined by the rigidity of the extracellular matrix (Goffin  et al., 
2006), further emphasizing the connection between the alterations in the cytoskeleton and 
stiffness of the matrix.  To further strengthen the evidence that alterations in the cytoskeleton 
of fibroblasts changes upon matrix stiffening, fibroblasts grown on soft gels do not have 
detectable stress fibers.  However, once fibroblasts are cultured on a stiffer matrix, stress 
fibers are ubiquitous (Yeung et al., 2005).  Aside from the synthesis of α-SMA, many other 
cytoskeletal proteins exhibit changes in expression upon myofibroblast differentiation, 
including α5β1 and αvβ3 integrins, vinculin, paxillin, talin, α-actinin, tensin, palladin and 
focal adhesion kinase (Dugina et al., 2001; Eyden, 2008; Rönty et al., 2006).  Interestingly, 
many of the proteins which change their expression also have different expression patterns in 
cancer, a characteristic that can alter both contraction and motility. 
As discovered by Salaria and others, palladin is upregulated in what appears to be the 
tumor-associated fibroblasts in pancreatic adenocarcinoma (Salaria et al., 2007).  Given that 
palladin has many functions in the actin cytoskeleton, such as formation of stress fibers, 
podosomes, and focal adhesions, and also motility, it is likely that palladin is playing a role 
in multiple features of tumor-associated fibroblasts.   
 The evidence that palladin is being upregulated by TGFβ1 in the wound healing 
environment is very applicable to the tumor microenvironment.  Earlier, it was noted that 
 35 
TGFβ1 plays a role in activating fibroblasts when secreted by tumor cells; therefore, the 
details of TGFβ1 signaling will be discussed in more detail.  For pancreatic cancer in 
particular, it is being recognized as an important drug target, which emphasizes its 
importance in the progression of cancer. 
 
Transforming Growth Factor β1 
 The TGFβ family of proteins has many functions in normal physiological settings, 
including self-renewal, selection of a differentiation lineage and maintenance of progression 
down that lineage (Derynck and Akhurst, 2007); they can also cause cells that have already 
started progression down one differentiation path to switch to another cell lineage.  TGFβ 
ligands are able to interact with serine/threonine kinase receptor complexes on the cell 
surface; there are two Type I receptors and two Type II receptors which can combine and 
result in Type I receptor activation.  Upon activation, Smad proteins are able to 
phosphorylate the carboxy terminal of the receptor and subsequently the Smad proteins and 
their effectors are able to regulate transcription programs.  In the case of TGFβ1, this ligand 
binds to the TGFβRII, and results in phosphorylation of the receptor that allows TGFβRI to 
complex with it.  Once this occurs, Smad3 is phosphorylated and able to interact with Smad4, 
leading to a translocation to the nucleus (B Hinz et al., 2007).  The majority of these 
transcriptional programs are important for differentiation, as demonstrated by the production 
of the myofibroblast marker α-SMA (Desmoulière et al., 1993; Vaughan et al., 2000).   
 The abundance of TGFβ1 in the tumor microenvironment may be playing multiple 
roles, such as in autocrine-paracrine signaling, inflammation, neoangiogenesis, and 
epithelial-stromal interactions (Mahadevan and Von Hoff, 2007).  In tumor cells themselves, 
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the role of TGFβ1 in differentiation may be activating a transcriptional program which 
results in epithelial to mesenchymal transition, or EMT.  In normal development, EMT is a 
common event and allows for the generation of different organs and tissues (Derynck and 
Akhurst, 2007).  Essentially, a highly organized sheet of epithelial cells transdifferentiates 
into a very disorganized, motile population of mesenchymal cells; interestingly, these cells 
resemble fibroblasts, which provides evidence to another theory on the origin of tumor-
associated fibroblasts, which is that they result from epithelial cells which have undergone 
this differentiation.  As this transformation occurs, cell adhesions are disassembled and the 
cytoskeleton is reorganized, forming stress fibers and focal adhesions (Derynck and Akhurst, 
2007).   Palladin is one of the genes modulated in this process (Alcorn et al., 2008).  Not 
surprisingly, EMT in tumor cells induced by TGFβ1 may cause them to differentiate 
completely into myofibroblasts, which confers the more migratory, contractile, and secretory 
phenotype, and it is clear how this would be advantageous to cells attempting to leave a 
tissue and implant elsewhere in the body. 
 As established in the section “Fibroblasts and the Stroma,” both a stiff extracellular 
matrix and an accumulation of TGFβ1 are required for fibroblast activation.  TGFβ1 is 
particularly important, as mechanical stress by itself is unable to induce the myofibroblast 
phenotype (Wipff et al., 2007).  There are indications that TGFβ1 is secreted by fibroblasts as 
a part of a latent complex, more specifically known as the Large Latent Complex (LLC), 
which consists of TGFβ1, Latency Associated Protein (LAP) and Latent TGFβ binding 
protein 1 (LTBP-1) (Wipff et al., 2007).  This complex binds to extracellular matrix 
components to serve as a store of latent TGFβ1.  For this TGFβ1 to become active, there 
must be an increase in tension in the extracellular matrix, as evidenced by the fact that this 
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phenomenon does not occur with more compliant substrates, only those with stiffness 
comparable to early wound granulation tissue (Wipff et al., 2007).  This type of substrate 
may be present early in tumor formation as well, resulting in continuous activation of 
fibroblasts in the stroma to further aid the tumor development.  It is important to note that 
activation of the latent TGFβ1 requires the resistance of functional stress fibers (Wipff et al., 
2007), which could be present either from tumor cells undergoing EMT, or from fibroblasts 
in the vicinity which have already been activated by a separate mechanism. 
 Overall, TGFβ1 signaling has significance in pancreatic cancer, as the status of the 
pathway may dictate clinical presentation (Chu et al., 2007) and the pathway, along with the 
consequences of the pathway (fibroblast activation) are increasingly being explored as a 
target for drug therapies (Henry et al., 2007), which also indicates the importance of the 
desmoplastic stroma in the progression of the disease.  With palladin being a target of TGFβ1 
signaling, it also could be a target of not necessarily therapeutics, but possibly for earlier 
detection.  Since it is upregulated early on in myofibroblast differentiation, possibly earlier 
than other standard markers like α-SMA, palladin could play an integral role in initial 
remodeling of the tumor microenvironment.  Therefore, it may have potential use as a 
biomarker for cancer progression and development.  Pancreatic cancer has proven to be a 
disease for which finding biomarkers is nearly impossible, so discovering a reliable marker 
could have vast implications for early detection and subsequent treatment. 
  
Biomarkers for Pancreatic Cancer 
Patients diagnosed early in the progression of pancreatic adenocarcinoma often have 
tumors that can be resected, and removing pancreatic tumors before they have spread to 
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surrounding organs increases the survival rate to anywhere between 15 and 40% (Goggins, 
2005) for one year and as much as 100% over five years (Zeh et al., 2005).  Thus, tests that 
can detect the presence of a tumor at an early, treatable stage are essential.  Currently, there 
are multiple methods to image the body in order to diagnose a pancreatic tumor and in 
addition, there have been attempts to find markers that are elevated in pancreatic 
adenocarcinoma which also circulate in the blood in the hopes that a routine blood test could 
diagnose the disease.  
Of the markers that have been studied as a possible blood or serum marker of 
pancreatic cancer, Carbohydrate Antigen 19-9 (CA19-9) is the most well-known.  CA19-9 is 
a sialylated Lewis blood group antigen that has proven most effective as a marker for disease 
recurrence and response to therapy.  In terms of diagnosis, there are benign pancreatic 
conditions such as chloestasis which can also cause elevated CA19-9 and subsequent false 
positives.  Furthermore, in patients already known to have pancreatic cancer, this antigen is 
elevated only about 65% of the time (Goggins, 2005), and in order for a marker to be 
sensitive and specific enough for use in the general population, the percentages for both must 
be closer to or at 100%.  It is also essential for the marker to reliably distinguish between 
chronic pancreatitis and pancreatic cancer, a requirement not met by any marker to date 
including CA19-9.  It has been proposed that a panel of cytokines, chemokines, and growth 
or angiogenic factors concomitantly with CA19-9 may provide an accurate blood/serum 
diagnosis of pancreatic cancer.  Many of these markers, such as IP-10 and HGF, were 
significantly higher in pancreatic cancer, and IP-10 was also able to differentiate between 
chronic pancreatitis and pancreatic cancer (Zeh et al., 2005). 
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Other markers besides CA19-9 that have been proposed as blood/serum markers for 
pancreatic cancer include: carcinoembryonic antigen (CEA), tissue of inhibitor 
metalloproteinase type 1 (TIMP-1), CA-195, mesothelin, osteopontin, and MIC-1 (Goggins, 
2005; Rustgi, 2005).  Though some of these, such as MIC-1, have shown to be effective at 
diagnosing pancreatic cancer, the hurdle of discerning between cancer and chronic 
pancreatitis has not been surmounted.   
For those individuals already known to be at risk for pancreatic cancer, particularly 
due to family history, certain genetic markers have been somewhat valuable in identifying 
those who may be at the highest risk.  Members of families known to have a history may be 
examined for mutations in BRCA2, p16, FANCC, mismatch repair genes, and cationic 
trypsinogen (Goggins, 2005).  These individuals can then be screened routinely, and 
therefore lesions can be found earlier and removed in the non-lethal stages.  In terms of the 
general population, finding useful genetic or epigenetic markers which can be detected in 
pancreatic juices is also not simple.  An example is the k-ras gene; mutations in this gene are 
found in about 90% of pancreatic adenocarcinomas, and its presence can be identified in 
pancreatic exudates.  However, mutations in k-ras are not limited to invasive pancreatic 
tumors, and are also found in chronic pancreatitis and in people who smoke (Goggins, 2005).  
As for epigenetic markers, detection of aberrant methylation patterns of various genes such 
as p16 and cyclin D2 are being explored as options for diagnosis. 
It is quite clear that a reliable biomarker for pancreatic cancer has yet to be identified.  
With such a highly lethal disease, the need for one is urgent.  Thus, palladin has become a 
more attractive candidate since it is consistently overexpressed in pancreatic cancer and 
shows stromal staining in immunohistological sections (Salaria et al., 2007).  With tumor-
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associated fibroblasts in the stroma becoming more important in cancer biology, the extent of 
palladin expression in these cells could also be a diagnostic indicator of aggressiveness, since 
there is a wound-healing phenotype associated with many cancers and it is correlated with a 
poor survival prognosis. 
 
Palladin and EUS-FNA 
 Endoscopic ultrasound-guided fine needle aspiration, or EUS-FNA, is a diagnostic 
method used for pancreatic cancer.  It was stated earlier that one of the difficulties with 
pancreatic cancer is that it is very difficult to diagnose early based on the location of the 
pancreas and the lack of symptoms, and imaging techniques are generally not sensitive 
enough to pick up small tumors.  The CT scan, a widely used imagining technique, is usually 
used to determine tumor size, location, extent of invasion, and regional vessel involvement 
(Pappas et al., 2007).  Given the cost of such imaging, it is not necessarily efficient to 
routinely perform CT scans or MRIs on individuals who are at risk for cancer.  EUS-FNA, 
however, is proving to be a technique that is highly sensitive and capable of detecting small 
tumors in a relatively non-invasive way, and when used with CT scanning, can dramatically 
increase tumor detection. 
 Essentially, an endoscope is inserted into the esophagus and guided down via camera 
to the wall of the stomach.  The scope also contains a fine gauge, sheathed needle which can 
be uncovered to poke through the stomach wall to the pancreas.  The needle can be guided to 
the area of a suspected mass, where several hundred cells can be sucked into the needle and 
later used for analysis.  This technique is safe and has a sensitivity level as high as 93% and a 
specificity level of about 82% (Gress et al., 2001); even more importantly, this technique was 
 41 
able to detect masses smaller than 2 centimeters in a study of 100 patients (Pappas et al., 
2007).  One of the problems with EUS-FNA, however, is that a cytologist needs to analyze 
the results, and with such a small sample size of cells, accurate analysis can be difficult even 
with a trained cytologist.  Without a specific biomarker for pancreatic cancer, cytologists are 
forced to detect potentially subtle changes in cell morphology, which often leads to negative 
diagnoses.  Accordingly, EUS-FNA is only performed at certain institutions and in families 
identified as being high-risk, which limits its possibilities as a diagnostic tool for the general 
public.  It is then necessary to find a biomarker which can be used on EUS-FNA samples to 
detect the presence of pancreatic cancer in these cell smears. 
Given the fact that palladin appears to be overexpressed in the stroma of a pancreatic 
tumor, and early in tumor development, it could be a candidate for a biomarker.  An EUS-
guided needle would have to pass through a zone of palladin positive stroma in order to get 
to the tumor cells.  Even if the needle did not obtain any actual tumor cells, simply staining 
the stromal cells obtained from the procedure could still provide an accurate diagnosis of 
cancer, potentially in early stages.  As with any biomarker, it would have to distinguish 
between benign chronic pancreatitis and pancreatic cancer.  If proven to differentiate 
between the two conditions, this would be a boon in the field of pancreatic cancer diagnosis 
and screening. 
 The goal of this study was to determine whether palladin was being overexpressed in 
the tumor cells, as postulated by the Brentnall paper, or in the cancer-associated fibroblasts of 
the stroma, as proposed by the Salaria study.  With the multiple palladin antibodies 
developed and used by the Otey lab, we were able to determine not only which cell type 
overexpresses palladin, but also which isoforms of palladin were differentially expressed in 
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tumor cells or tumor-associated fibroblasts.  Moreover, different antibodies raised against 
palladin were able to distinguish between benign pancreatic conditions and adenocarcinoma 
by immunohistochemistry, which supports the potential for palladin as a marker to be used in 
EUS-FNA.  Additionally, the Salaria paper determined that palladin was being expressed in 
tumor-associated fibroblasts based on the morphology of cells stained in the tumor stroma.  
There are numerous cell types in the tumor microenvironment, and it was important to verify 
palladin expression specifically in the activated tumor-associated fibroblasts.  Consequently, 
we used a marker of activated fibroblasts to demonstrate the presence of palladin specifically 
in these cells.   
 
Summary 
 The actin cytoskeleton is a system of microfilaments regulated by a multitude of 
proteins which allow it to function in motility, adhesion, and contractility.  These actin 
binding proteins are able to arrange actin filaments into different types of arrays.  Dendritic 
arrays allow for cell protrusion and motility; parallel and antiparallel arrays function in 
contractility and formation of adhesions.  Contractile arrays in the form of stress fibers are 
regulated by bundling and cross-linking proteins, which are in turn regulated by the Rho 
family GTPase, RhoA.  Palladin is a cross-linking and scaffolding actin binding protein with 
multiple isoforms that is important in stress fibers and other actin structures like cell 
adhesions; it also has been found to have roles in motility.  On a broader scale, palladin is 
important in development for neural tube and body wall closure, is upregulated early in the 
fibroblasts involved in wound healing, and has been discovered as being part of an invasive 
signature of gene expression in breast cancer tumor cells.  Palladin is also overexpressed in 
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the tumor-associated fibroblasts of pancreatic adenocarcinoma, and a single palladin 
mutation has been found to cause pancreatic cancer in a large kindred.  Tumor-associated 
fibroblasts are an emerging field of study in the cancer field; resembling wound healing 
fibroblasts in phenotype, these cells are more motile, secretory, and contractile, and seem to 
be playing an important role in both stimulating tumor cells to proliferate and remodeling the 
extracellular matrix so tumor cells can invade and metastasize.  Tumors with these activated 
fibroblasts in the stroma are associated with a poorer prognosis, as the wound healing 
molecular program is constitutively turned on and creates a negative feedback loop within 
the microenvironment; tumor cells are continually secreting factors to activate fibroblasts and 
in turn, activated fibroblasts are continually secreting factors to stimulate proliferation and 
motility in the tumor cells.  This excess of fibrotic tissue is known as desmoplasia, and it is a 
unique feature of pancreatic adenocarcinoma. 
 The lack of biomarkers in pancreatic cancer has made progress in understanding this 
disease quite slow; there also seems to be an entirely different mechanism of tumor 
development and invasion in this kind of cancer, as it metastasizes so rapidly.  The 
upregulation of palladin by TGFβ1 in wound healing fibroblasts seems to be mimicked in the 
tumor microenvironment, where there is an excess of TGFβ1.  The upregulation of palladin 
occurs early in pancreatic tumor development, as it does early in fibroblast activation, which 
means that palladin may have a future as a biomarker for pancreatic cancer, making detection 
easier and giving more opportunities for treatment.  EUS-FNA is a technique which provides 
very accurate diagnosis of pancreatic cancer, but is in need of a highly specific biomarker; 
based on palladin’s spatial and temporal expression in pancreatic tumors, it has the potential 
to be a very accurate biomarker for use in EUS-FNA.  Additionally, unlocking the role of 
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palladin in these tumor-associated fibroblasts, where it could be involved in their 
hypercontractility, secretion, or increased motility, could provide some insights into the 
seemingly distinct mechanism of pancreatic cancer progression.   
 
 
 
 
Multiple Palladin Isoforms are Expressed in Pancreatic Cancer 
 
Three isoforms of palladin resolving at 90, 140, and 200kD have been described 
previously (Parast and Otey, 2000; Rachlin and Otey, 2006).   However, when the structure 
of the gene was first described, it was noted that at least two other smaller isoforms were 
likely to exist (Rachlin and Otey, 2006).  Further analysis of the transcriptome database has 
shown that there may be as many as seven isoforms of palladin in humans.  As of yet, the 
exact sequence of the newer isoforms has not been confirmed experimentally (Figure 1).   
According to the numbering system of the Universal Protein Database, the canonical 
isoforms of palladin are #1 (200kD), #3 (140kD), and #4 (90kD) (Figure 1).  Although the 
new isoforms are significantly different from the classical isoforms, they all share common 
domains.  We have examined the structure of these isoforms and found that domains known 
to be important in palladin function are spliced out.  Isoforms #2, 5 and 7 do not have 
proline-rich domains, which have been shown experimentally to be important for palladin 
binding to proteins like profilin (Boukhelifa et al., 2006), VASP (Boukhelifa et al., 2004), 
Lasp-1 (Rachlin and Otey, 2006), Src (Rönty et al., 2007) and Eps8 (Goicoechea et al., 
2006).  Additionally, isoform #6 lacks Ig domains 3, 4, and 5 (Figure 1).  Ig3 has been 
identified as the minimum fragment necessary for actin-binding (Dixon et al., 2008).  
Conversely, isoform #7 exclusively contains Ig domains 3, 4 and 5 (Figure 1).  Based on this 
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data, we can speculate that these uncharacterized palladin isoforms may have unusual 
binding partners or functions in the cell. 
The Otey lab has multiple palladin antibodies that can be used to study the expression 
levels and localization of palladin isoforms.  Polyclonal antibodies 622 and a commercially 
available polyclonal (henceforth referred to simply as Commercial) were developed as pan-
palladin antibodies, with fragments targeting multiple regions of the protein.  The 
monoclonal antibodies 1E6 and 4D10 target a specific region in the middle of the palladin 
protein.  These antibodies can provide us with information on the well-characterized palladin 
isoforms and also on the newer isoforms.  Eventually it will be necessary to confirm the 
expression levels of the isoforms using a second quantitative method such as qPCR.  
However, for characterization and localization studies, the polyclonal and monoclonal 
antibodies are very useful. 
We performed western blots to examine palladin expression in three pancreatic 
cancer cell lines, AsPC-1, Mia-PaCa, and Panc-1, and used a control pancreatic ductal 
epithelia cell line, HPDE, for comparison.  The tumor cell lines express virtually the same 
amount of palladin isoform #4 of palladin as the control (Figure 2B).  Additionally, we 
looked at palladin expression in normal gingival fibroblasts and compared with a tumor-
associated fibroblast cell line obtained from explants of a human pancreatic tumor.  The 
tumor-associated fibroblasts expressed significantly more of isoform #4 than the normal 
fibroblasts (Figure 2A), and a longer exposure time revealed more isoforms that were not 
present in the control fibroblasts (Figure 2C).  With the polyclonal antibody 622, six of the 
seven palladin isoforms were detected in the tumor-associated fibroblasts (Figure 2C), while 
only isoform #4 was expressed in the tumor cell lines.  With the 1E6 antibody, bands of 
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isoform #4 only appeared in normal and tumor-associated fibroblasts, indicating specificity 
of palladin expression in this cell type.  This supports the immunohistological data from 
Salaria et al indicating that palladin was expressed at higher levels in the stromal cells 
surrounding the tumor, and not in the tumor cells themselves.   
 
Immunohistological Scoring Shows Monoclonal Palladin Antibodies Can Differentiate 
Between Pathological Pancreatic Conditions 
 
 Next, we examined palladin expression in human tissue samples to confirm the 
results of the Salaria paper.  The results were then scored by a pathologist to determine 
whether epithelial or stromal cells expressed palladin in benign and malignant tissue.  The 
622 and 1E6 antibodies were used along with Commercial and 4D10 to stain paraffin-
embedded samples of normal pancreas, chronic pancreatitis, and pancreatic tumors.  The 
immunohistochemistry from two of these antibodies, Commercial and 1E6, is shown in 
Figure 3.  The polyclonal Commercial antibody (Figure 3A) generated a higher signal in both 
the epithelial and stromal cells, but the pattern of staining did not differ noticeably between 
the three conditions.  The monoclonal 1E6 (Figure 3B) had a lower overall signal in the 
tissue sections, but the staining is only in the stromal cells, and not in both cell types, as seen 
with the polyclonals.  More importantly, the signal is stronger in the stromal cells of 
adenocarcinoma than in chronic pancreatitis, indicating that monoclonal palladin antibodies 
can distinguish between benign pancreatic inflammation and cancer.  The 
immunohistochemistry data also support the palladin expression detected by 1E6 in Figure 
2C, where palladin was expressed exclusively in fibroblasts. 
Ten samples from each of the conditions in Figure 3 were scored blindly by a 
pathologist who did not know the diagnosis of each tissue section.  The point of the scoring 
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was to examine the epithelial cells and stromal cells separately and determine which cell type 
exhibited a different pattern of palladin staining between normal, chronic pancreatitis, and 
adenocarcinoma.  The quantification method involved combining two different scores.  The 
sections were assigned a value from 1 to 4 based on the intensity of the staining, and a 
second value between 1 and 6 that was based on the percentage of cells stained.  The highest 
number, 6, meant more than 75% of cells stained positively.  The values from the percentage 
of cells stained and the intensity of the staining were combined and multiplied, resulting in a 
score between 0 and 24.  These are the values shown in Figure 4.  Figure 4A represents the 
score for epithelium staining by 622, Commercial, 1E6 and 4D10.  The scoring indicates that 
these antibodies could not differentiate between normal, chronic pancreatitis, and tumor by 
staining in the epithelial cells.  The numbers are close in value, with normal pancreas 
epithelium actually scoring higher in intensity and percentage of cells stained than epithelial-
derived tumor cells.  Quantitatively, the polyclonal antibodies have a higher staining intensity 
than the monoclonal antibodies.  The polyclonals scored 15-20 on the three tissue types, 
while the monoclonals scored less than 5.  We concluded from this data that palladin staining 
in epithelial cells is not different between the three conditions. However, scoring the stromal 
staining with these four antibodies produced very different results (Figure 4B).  Both of the 
monoclonal antibodies, 1E6 and 4D10, show lower scoring in chronic pancreatitis and 
normal compared to tumor by as many as 5 points.  Even with lower staining intensity, the 
distinction between the three conditions is clear.  The polyclonal antibodies, 622 and 
Commercial can distinguish between tumor and normal. However, these antibodies 
distinguish only moderately well between chronic pancreatitis and tumor.   This scoring data 
indicates that palladin staining can distinguish between the three conditions based on staining 
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in the stromal cells and not the epithelial cells.  The data also supports the results from the 
Salaria paper showing that palladin is expressed in the stroma of pancreatic tumors.  
Additionally, the scoring and immunohistochemistry data indicates that the 
monoclonal palladin antibodies, and not the polyclonals, can distinguish between chronic 
pancreatitis, normal pancreas, and pancreatic adenocarcinoma based on differences in 
intensity of staining in the stromal cells.  This data corroborates the staining in Figure 3 
indicating that the monoclonal antibody 1E6 specifically and distinctly stained the stromal 
cells of each sample while the polyclonal Commercial stained both the epithelial and stromal 
cells.  This observation emphasizes the potential of palladin and its monoclonal antibodies as 
a biomarker for use in samples of pancreatic tissue. 
 
Palladin is Overexpressed in Highly Invasive Pancreatic Tumors 
 Pancreatic adenocarcinomas are known for being invasive and aggressive.   There are 
also pancreatic tumors that are very different from adenocarcinoma in that they grow rapidly 
but rarely metastasize.  We wanted to know if palladin expression levels in these less 
invasive tumors are similar to levels in invasive adenocarcinoma.  Using samples from two 
less invasive tumor types (solid pseudopapillary and neuroendocrine), normal pancreas, and 
invasive adenocarcinoma, we looked at palladin protein expression with multiple antibodies 
(Figure 5). 
 Lanes 1 and 2 are normal pancreas tissue; lanes 3, 4 and 5 contain samples of 
adenocarcinoma tumors; and lanes 6 and 7 contain samples of solid pseudopapillary and 
neuroendocrine tumors.  Normal pancreas expresses almost no palladin with the exception of 
a band detected by the 622 antibody.  This is not surprising given the data with 622 in Figure 
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2C that showed HPDE cells expressing palladin.  The amount of palladin in the 
adenocarcinoma cells is higher than the control, except with the 622 antibody.  This also 
supports the data with the 622 antibody in Figure 2C, where tumor cell lines expressed about 
the same amount of palladin as the HPDE cells.  In the tumor samples, the 622 antibody 
detects less of the band found in normal pancreas, which suggests this isoform may be 
downregulated in tumor tissue.  A strong band is detected right above this isoform, which 
might indicate a different isoform or a post-translational modification of the same isoform, 
causing it to run at a slightly higher molecular weight.  Lanes 6 and 7, the pseudopapillary 
and neuroendocrine tumors, express approximately the same amount of palladin as the 
normal pancreas.  The graph quantifies the data and further illustrates the differences in 
expression levels between the three samples (Figure 5).  Palladin overexpression is limited to 
invasive pancreatic adenocarcinomas, meaning it may have a role in promoting invasion of 
tumor cells.   
 
Palladin is Expressed in Tumor-Associated Fibroblasts of Pancreatic Tumors 
 Protein expression data indicated that palladin is overexpressed in the fibroblasts 
associated with a pancreatic tumor.  However, the immunohistochemistry data did not 
unequivocally indicate the cell type expressing palladin.  The Salaria paper saw palladin 
expression in the area surrounding the tumor.  Based on this stromal staining, they concluded 
that the tumor-associated fibroblasts expressed palladin.  Although these cells are abundant 
in the microenvironment, we know multiple cell types are present in the area surrounding the 
tumor.  Therefore, a more precise assay was necessary to pinpoint palladin to the population 
of tumor-associated fibroblasts.  We therefore examined the co-localization of palladin with 
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an activated fibroblast marker, alpha smooth muscle actin (α-SMA), to confirm that palladin 
was being expressed specifically in these cells. 
 Using human tissue samples, we performed double staining with a palladin antibody 
and the accepted marker for activated fibroblasts, α-SMA.  The immunofluorescence images 
in Figure 7 show that there is a high degree of overlap of staining in the activated fibroblast 
population.  Thus, palladin staining is specific to the population of activated tumor-associated 
fibroblasts. 
 
Discussion 
 In this study, we found that (1) palladin is overexpressed in fibroblasts associated 
with pancreatic adenocarcinoma tumors, but not in normal fibroblasts or pancreatic tumor 
cell lines, and (2) palladin is specific to highly invasive pancreatic tumor types.  
The discovery that palladin, a cytoskeletal protein, is playing a role in the tumor 
microenvironment by being overexpressed in tumor-associated fibroblasts is surprising.   As 
indicated in the section on “Cytoskeleton Proteins and Cancer,” many studies have shown 
that cytoskeleton proteins play a role in the tumor cells themselves, and roles for these 
proteins in the microenvironment have not been extensively examined.  The idea that the 
tumor microenvironment is advantageous to growth and invasion, along with the data that 
suggests that mutations in fibroblasts could promote tumor formation, indicates that this area 
needs more research in order to fully understand mechanisms of carcinogenesis.  This is 
particularly true in the case of pancreatic cancer, a disease that is host to a rich 
microenvironment and impervious to treatment and progress in early detection.  Since a 
palladin mutation has been identified as a causative factor in a form of familial pancreatic 
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cancer, this raises many questions.  For example, is palladin being mutated in the tumor cells 
of this family, or is it a stromal mutation causing the disease?  At this point, that is unclear.  
With members of Family X dying at a young age, it has not been possible to document the 
development of other diseases later in life that may result from a stromal mutation.  As a 
result, the cellular role of palladin in this particular family has yet to be fully described.  
Another question is that if palladin can be detected in precancerous lesions in this family, 
could it be used as a biomarker in the general population?   Obtaining samples of PanIN 
lesions for examination by immunohistochemistry is difficult given the small number of 
patients diagnosed at these stages.  However, it will be important to look at palladin 
expression in these lesions since we do not know if the same pattern of palladin staining 
exists early in tumor formation.  If it does, there is potential for palladin as a diagnostic 
indicator; a protein reliably expressed early in the development of pancreatic cancer could 
detect tumors or precancerous lesions at a treatable stage.  Finally, a palladin mutation 
causing cancer adds new importance to the argument on the role of cytoskeletal proteins in 
tumor development and invasion, and raises the question of what a protein like palladin, 
which is involved in stress fiber formation and wound healing, is doing in the tumor 
microenvironment.  At present, we do not know the consequences of this upregulation in 
tumor-associated fibroblasts. 
 When considering the question of whether or not palladin could be a biomarker for 
early detection of pancreatic cancer, it is important to define what makes a good biomarker 
and whether or not palladin fulfills these characteristics.  As discussed in the section 
“Biomarkers for Pancreatic Cancer,” it is essential for a biomarker candidate to be both 
sensitive and specific.  This means it must be specific to pancreatic cancer and not detected 
 52 
in other conditions, especially benign diseases like chronic pancreatitis, and it must be 
sensitive enough to identify any tumor without false negatives or positives.  At this point, 
many of the proposed biomarkers rank high on sensitivity and specificity, but not high 
enough in both for use in the general public.  Also, the biomarker must be present early in the 
development of precancerous lesions, a stage where therapeutic intervention has the most 
success.  Palladin is expressed at the mRNA level in precancerous lesions (Pogue-Geile et 
al., 2006).  However, we do not yet know how palladin expression changes through 
progression of PanIN lesions into cancer.  The current study demonstrates that monoclonal 
palladin antibodies can distinguish between benign chronic pancreatitis and tumor based on 
differences in stromal staining (Figures 3 and 4), suggesting that one palladin isoform is 
upregulated specifically enough to distinguish between benign and cancerous disease.  In 
addition, palladin expression is limited to invasive tumors (Figure 5), strengthening the 
argument that it is highly specific.  The sensitivity aspect needs more examination; however, 
since palladin is overexpressed in the stroma of over 96% of pancreatic tumors (Salaria et al., 
2007), it seems likely that palladin levels are more accurate at identifying a tumor than 
CA19-9, which is only found in about 80% of pancreatic cancers. 
 In order to solve the issue of palladin’s status in the development of pancreatic 
cancer, we plan to use a mouse model.  Hingorani and others have developed a mouse model 
with mutant K-RAS that mimics the development and progression of pancreatic cancer, 
starting with PanIN lesions and progressing to adenocarcinoma (Hingorani et al., 2003).  The 
Otey lab will use tissue sections from this mouse to examine palladin staining in 
precancerous lesions from this mouse.  The results from this staining will give us information 
about palladin protein expression in these lesions and may confirm the mRNA data from the 
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Brentnall lab, with palladin detected at appreciable levels and increasing over time as the 
lesion progresses (Pogue-Geile et al., 2006).  If so, palladin will have even more potential as 
a marker in EUS-FNA samples.  However, mouse models are not always identical to 
humans, so this will leave open the possibility that while detectable in mouse PanIN lesions, 
the palladin expression pattern will not be the same in human lesions.  This mouse K-RAS 
mutant is a valuable model because K-RAS is mutated in a large percentage of pancreatic 
cancers, but not all tumors develop from this mutation, meaning the progression through 
carcinogenesis may differ depending on the origin of genetic instability.  While this is also an 
issue, it is a useful model to study the stages of PanIN lesions.  Until human samples of 
PanIN lesions become more readily available, a mouse model is the best option.   
 If palladin is found to be a sensitive and specific biomarker that is detectable early in 
progression of cancer, it can be used to stain EUS-FNA samples.  One of the reasons this 
highly sensitive test is not done frequently is the lack of a good marker.  Cytologists looking 
primarily at differences in cell morphology can make mistakes in diagnosis without a distinct 
marker.  Tracking palladin expression either by staining the cytological samples or through 
quantitative PCR would increase the availability of EUS-FNA to the general public, as 
staining cell smears or quantitative PCR are not difficult and require less interpretation.  
Applying EUS-FNA screening to a larger number of people would be as revolutionary as 
mammography and colonoscopy in terms of early detection.  Since pancreatic cancer is a 
uniformly lethal disease, earlier detection will have dramatic implications on the death rate of 
pancreatic cancer and on treatment options.  Previous studies have shown that pancreatic 
tumors detected at a size of 2 cm or smaller can be removed and the chances for survival 
increase dramatically as a result, to even 100% over 5 years (Zeh et al., 2005).  If palladin 
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can be used to detect small tumors in EUS-FNA, this will make up for the insufficiency of 
imaging techniques like the CT scan to detect small tumors. 
Determining the consequences of palladin upregulation in the tumor-associated 
fibroblasts is an important task.  Given that tumor-associated fibroblasts are highly 
contractile, secretory, and motile, all processes requiring the cytoskeleton, palladin may be 
involved in one or more of these.  Palladin is an integral part of stress fibers, structures that 
are important for maintaining contractility and stiffness in cells.  High contractility and 
stiffness in the microenvironment is important for developing the tension which can promote 
tumor formation (Paszek and Weaver, 2004), and enhance the release of growth factors and 
activate mechanotransduction pathways.  Other studies have shown that palladin is 
upregulated in wound-healing fibroblasts in response to TGFβ1 release (Rönty et al., 2006); 
there is evidence for increased TGFβ1 signaling in cancer, and tumor-associated fibroblasts 
appear to be activated by this TGFβ1 in the microenvironment.  Therefore, we think it is 
likely that palladin is being upregulated in fibroblasts in the tumor microenvironment in 
response to activation by TGFβ1.  Based on work by Ronty et al, this may be an early event 
in both tumorigenesis and fibroblast activation (Rönty et al., 2006).  Upregulation of at least 
one palladin isoform is seen as early as 24 hours after treatment with TGFβ1, and it is 
reasonable that in an environment as hypercontractile as the tumor microenvironment, this 
isoform could be upregulated even earlier.  Additionally, the other palladin isoforms specific 
to the TAFs could be upregulated early.   
Aside from TGFβ1, palladin appears to be sensitive to regulation by mechanical 
forces. Through regulation by mechanotransduction pathways, palladin may have a role in 
creating a stiff microenvironment.  Studies in osteogenic differentiation showed that palladin 
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expression increased in response to tensile strain (Wall et al., 2007), and anecdotal evidence 
from the author of palladin expression in normal fibroblasts indicates that palladin may be 
constitutively expressed in these cells due to plating on a hard plastic substrate.  Cell 
adhesions, particularly focal adhesions, are becoming more and more likely candidates for 
the mechanosensors in cells, and in the section “Tumor-Associated Fibroblasts and 
Cancer,” a model for mechanotransduction involving integrins is discussed.  Also, in 
myofibroblasts, the cells phenotypically identical to tumor-associated fibroblasts, 
mechanosensing is achieved by the specialized focal adhesions.  Palladin appears to stabilize 
β1-integrin, an essential component of focal adhesions (Liu et al., 2007), and is found in cell 
adhesions (Parast and Otey, 2000).  Thus, palladin may be part of a mechanotransducing 
pathway activated in response to a stiffened extracellular matrix promoted by tumor cell 
growth.  Since stress fibers and focal adhesions are connected, palladin may be stabilizing 
β1-integrin and consequently focal adhesions in response to mechanical stress.  This 
stabilization aids in the formation of stress fibers.  Given that RhoA is important for both 
focal adhesions and stress fibers, and that palladin may interact with Rac GTPase 
(Goicoechea et al., 2006), palladin might interact with Rho in these mechanosensing 
pathways.  The Otey lab plans to look at a possible palladin-Rho interaction in the future. 
 A likely scenario for palladin’s role in contractility is that tumor formation in the 
ducts of the pancreas creates tension in the tissue surrounding the tumor cells, which in turn 
puts pressure on the extracellular matrix.  In response to this hardened matrix, 
mechanotransduction pathways activate in nearby resident fibroblasts, probably though 
sensing by focal adhesions.  The fibroblasts become partially activated and stress fibers begin 
to form in response to the activation and the hardened matrix.  As the fibroblasts activate 
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they secrete growth factors like TGFβ1.  TGFβ1 in the extracellular environment can feed 
back in an autocrine fashion and further activate fibroblasts, causing them to differentiate 
further into myofibroblasts.  This increases palladin levels and stress fiber formation.  TGFβ1 
may also be released by the tumor cells to activate the fibroblasts and upregulate palladin 
further.  The highly contractile fibroblasts stiffen the matrix even more, secrete growth 
factors and metalloproteinases, and subsequently promote tumor growth and invasion.  Thus, 
palladin and its role in contractility may help establish this matrix-stiffening feedback loop in 
the desmoplastic reaction surrounding a pancreatic tumor. 
 Palladin is a part of stress fibers, and stress fibers are important for contractility.  So, 
it is likely that palladin is playing a role in the contractile microenvironment. Nevertheless, 
this does not rule out palladin upregulation in tumor-associated fibroblasts having a role in 
their motility or secretion.  There is already evidence that the tumor-associated fibroblasts 
have a role in leading tumor cells out of the primary tumor (Gaggioli et al., 2007).  What is 
not known is how palladin would fit into this model.  Palladin is important for motility, most 
likely through the stress fibers necessary to create tractional force, or through the focal 
adhesions providing footing for the cells.  Overexpressing palladin, however, causes 
increased stress fiber formation, a characteristic that would seem to inhibit movement.  As a 
result, palladin’s role in motility in these cells remains unclear.   
 The highly secretory nature of these activated fibroblasts could reveal a unique role 
for palladin in secretion.  The actin cytoskeleton is essential for exocytosis; rearranging actin 
filaments to accommodate vesicle fusion is an important part of the process.  A protein like 
palladin which is important for stress fibers and adhesions doesn’t seem like a likely 
candidate.  Yet, dissecting the cytoskeletal proteins known to have a role in secretion could 
 57 
reveal a more indirect role for palladin.  For example, Rac is proposed to have a role in 
primary granule exocytosis in neutrophils (Mitchell et al., 2008), and a decrease in palladin 
decreases Rac activation (Goicoechea et al., 2006).  Myosin II, which is the molecular motor 
essential for contractility, is required for at least one type of exocytosis (Doreian et al., 2008).  
Palladin is one of the building blocks of stress fibers, which contain myosin II.  Accordingly, 
there may be a connection between these two actin-binding proteins in the rearrangement of 
the cytoskeleton for secretion.  Therefore, while palladin may not be required for secretion in 
activated fibroblasts, it could play a supporting role in the release of growth factors and 
metalloproteinases into the microenvironment. 
Additionally, there is the anecdotal observation that palladin localizes to the nucleus 
of several cell types.  This means that palladin may be redistributed to a completely different, 
non-cytoskeleton role in the tumor-associated fibroblasts.  As of yet, the localization of 
palladin in these cells on a subcellular level is unknown.  With multiple isoforms of palladin 
present in these cells and the fact that the functions of several of these isoforms is unknown, 
it is possible that one of them is targeted to the nucleus of cells, where it can affect 
transcription of other target genes.  Other cytoskeleton proteins like actinin-4 have been 
found in the nucleus in tumor cells, so palladin may also have a functional role in the nucleus  
Unpublished data from our lab showed that when isoform #7 is transfected into cells, it 
localizes preferentially to the nucleus, adding more evidence to a role for palladin in the 
nucleus of some cell types. 
With such a multitude of possibilities for palladin function, studying its role is 
essential and will provide new insights into the role of the tumor microenvironment in the 
development and progression of pancreatic cancer.  Also, through studying palladin’s 
 58 
regulation in cancer, new pathways and possible therapeutic targets may be discovered.  
Additionally, if palladin is playing an early role in tumor progression, the potential for 
biomarker status cannot be ignored.  The next steps in determining the regulation and role of 
palladin in tumor-associated fibroblasts are outlined in the next section, “Future 
Directions.” 
  
Future Directions 
 The goal of this study was to identify the cell type expressing palladin in pancreatic 
cancer.  Our results showed that palladin is expressed in the tumor-associated fibroblasts of 
pancreatic tumors.  Additional areas for further investigation include determining the 
function of palladin in the tumor-associated fibroblasts.  However, there are other necessary 
pieces of the palladin puzzle that need to be studied.  For example, although experiments in 
wound healing models indicate that some isoforms of palladin are upregulated as early as 24 
hours after treatment with TGFβ1, in a cancer setting, could some palladin isoforms be 
upregulated even earlier?  If this upregulation is an early event in the activation of 
fibroblasts, could that have promise in a diagnostic setting?  Next, while TGFβ1 has been 
shown to upregulate palladin consistently in the activation of fibroblasts, and there is 
evidence of TGFβ1 activity in pancreatic cancer, could there be other growth factors secreted 
by tumor cells that can activate fibroblasts and consequently upregulate palladin?  These are 
questions that must be answered in order to have a more complete picture of the palladin 
story in pancreatic cancer. 
 Normal fibroblasts provide a good model system for studying palladin upregulation 
since they can be activated by treatment with TGFβ1.  One obstacle in studying palladin 
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upregulation in these cells comes from the fact that palladin may be a mechanosensitive 
protein, as discussed previously.  The typical cell culture method of plating fibroblasts on 
plastic partially activates fibroblasts (B. Hinz, 2007), resulting in palladin upregulation even 
in untreated fibroblasts, visible through western blot analysis.  Therefore, it is necessary to 
utilize a culture system that will eliminate the possibility of partial activation.  Accordingly, a 
culture system based on the idea of culturing fibroblasts in collagen disks has been adapted 
(Nakagawa et al., 1989) and modified for use in studying palladin protein expression.  
Allowing the fibroblasts to grow in a collagen disk eradicates mechanical activation, as the 
collagen substrate is softer and more physiologically realistic than plastic plates.  With this 
culture system, we can examine palladin upregulation accurately and precisely in these cells.  
TGFβ1 as a stimulant of palladin upregulation is the most obvious choice for these 
experiments.   We cannot assume it is the only factor affecting palladin expression.  
However, since it has already been proven to affect palladin expression in a wound-healing 
environment, it is the best place to start.  Upon treatment of normal fibroblasts with TGFβ1, 
time points between 0 and 24 hours will be taken.  Fibroblasts can be extracted easily from 
collagen disks and processed for use in western blot analysis, and we will use this technique 
to study palladin expression.  We will also examine palladin expression at these time points 
with multiple antibodies, since only isoforms #3 and #4 were studied previously in the 
context of fibroblast activation (Rönty et al., 2006), with the earliest time point being 12 
hours.  Once a general time frame has been established, more detailed time points will be 
taken to obtain a complete time course of palladin upregulation in fibroblast activation.  
Knowing this information will have broad implications for the use of palladin as a diagnostic 
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marker, since many of the known biomarkers like CA19-9 are only present later in the 
progression of pancreatic cancer, doing little for the patient or for treatment options.   
 Aside from the time course of palladin upregulation in activated fibroblasts, we will 
explore the possibility that other growth factors are involved in this process.  TGFβ1 is the 
most obvious candidate.  However, with everything from FGF to VEGF being present in the 
microenvironment, one or more of these factors could be contributing as well.  Accordingly, 
the use of conditioned media, or media that has been used for growth of pancreatic cancer 
cell lines and therefore contains whatever products have been secreted by the tumor cells, is 
the best place to start separating out these other factors.  Using the culture system of 
fibroblasts mentioned in the above paragraph, we will apply conditioned media to the 
fibroblasts in the collagen disks and watch for palladin upregulation.  Of course, if we still 
observe palladin upregulation, this does not rule out TGFβ1 as being the master regulator.  In 
view of that, we will add inhibitors of TGFβ1 in the form of Smad or p38 inhibitors to the 
conditioned media.  If palladin expression still increases, we can deduce that some other 
factor is involved in the microenvironment that can affect palladin expression and possibly 
activate fibroblasts.  Obviously, this will incur more tests to narrow down exactly which 
growth factors are involved, and more focus would also be placed on the actual pathway to 
palladin upregulation.  
 The assays to determine the function of palladin upregulation in the tumor-associated 
fibroblasts will initially focus on a contribution to contractility.  The best way to examine 
contractility is to use a quantitative method that can also utilize the culture system of 
fibroblasts being seeded in collagen.  Collaborators of the Otey lab, Dr. Elizabeth Loboa’s 
lab at NC State, have adapted a machine that exposes cells seeded in these matrices to cyclic 
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tensile strain (Pfeiler et al., 2008).  Reaction of the cells is seen through deformation of the 
matrix and measured quantitatively.  This technique has already been used to examine 
palladin upregulation in human adipose-derived stem cells (Wall et al., 2007).  The tensile 
strain would mimic the alterations of the extracellular matrix seen in early tumor 
development and fibroblast activation.  This will be applied to both normal fibroblasts 
overexpressing palladin and tumor-associated fibroblasts where palladin has been knocked 
down.  Ideally, the normal fibroblasts overexpressing palladin will be hypercontractile, and 
the tumor-associated fibroblasts lacking palladin will exhibit low, if any, contractility.  This 
would implicate palladin as part of the machinery that remodels the extracellular matrix in 
the microenvironment. 
 The major obstacle for these experiments is the manipulation of palladin expression.  
While an overexpression lentivirus has been developed and shown to be successful at 
overexpressing palladin with high efficiency of infection in multiple cell types, knocking 
down palladin is a more difficult task.  With as many as six isoforms being present in the 
tumor-associated fibroblasts (Figure 2C), and little knowledge as to which of these isoforms 
are performing a function in the cells, it will be necessary to knock down each of the 
isoforms in order to eliminate any and all palladin function.  Since we do not know the exact 
sequence of some of these isoforms, developing a strategy to knock all of them down will be 
difficult and time-consuming.  Adding to that is the necessity for a highly efficient 
knockdown, which is not easily achieved with most methods.  Thus, while examining the 
consequences of palladin upregulation is the most important aspect of this project, it will also 
prove to be the most challenging due to the technical portions involved.   
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Conclusion 
The tumor microenvironment is a complex mixture of tumor cells, inflammatory 
cells, blood vessels, and mesenchymal cells.  In pancreatic cancer, this microenvironment has 
an excess of fibroblasts and extracellular matrix, and is known as desmoplasia.  This feature 
is one of the challenges of pancreatic cancer, as its presence signals a more aggressive and 
metastatic tumor.  Palladin, an actin-binding protein with roles in cell adhesion, motility, and 
contractility, is overexpressed and mutated in a form of familial pancreatic cancer, and 
overexpressed in sporadic pancreatic adenocarcinoma.  Evidence points to palladin being 
overexpressed in the activated fibroblasts of the tumor microenvironment, a subset of cells 
that phenotypically resemble wound healing fibroblasts and are more motile, secretory, and 
contractile than normal fibroblasts.  Tumors are increasingly being compared to “wounds that 
will not heal,” since many of the same molecular programs are induced in both situations.  
Palladin is also upregulated in activated fibroblasts in wound healing, which leads to the 
conclusion that palladin may be a part of the wound healing signature found in more 
aggressive tumors, and could be playing an integral role in these tumor-associated 
fibroblasts.  Closer investigation has found that multiple palladin isoforms are expressed at 
high levels in these fibroblasts.  Studying the pathways resulting in palladin upregulation 
along with the consequences of upregulation will provide clues into the mechanism of this 
very lethal disease, and eventually palladin may become a diagnostic marker for pancreatic 
cancer. 
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Figure 1: Reported Human Palladin Isoforms and their Characteristics 
 
 
 
 
Figure 1: The chart shows the isoforms of palladin reported in the transcriptome database.  
The numbers were assigned by the Universal Protein (UniProt) database.  The predicted and 
apparent molecular weight are noted because palladin often runs higher in gels due to the 
presence of proline-rich domains.  The domain structure indicates the presence of Ig domains 
(blue boxes) and proline-rich domains (red boxes).  Isoforms #1, #3, and #4 have been 
published and characterized as the classical palladin isoforms, and #2, #5, and #7 are the 
sequences reported in the database, but not yet confirmed experimentally. 
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Figure 2: Palladin Protein Levels and Isoforms Expressed in Pancreatic Cancer Cell 
Lines and Fibroblast Cells 
 
 
 
Figure 2: Western Blot analysis of palladin in cell lines.  A.) Palladin levels in normal 
fibroblasts (NF) and tumor-associated fibroblasts (TAF), with tubulin as a loading control.  
TAFs express significantly more palladin than the normal, unactivated fibroblasts.  B.) 
Levels of palladin protein expression in a normal pancreatic ductal epithelial cell line 
(HPDE) and in three pancreatic cancer cell lines (Panc-1, Mia-PaCa, and AsPC-1), with 
tubulin loading control. All cell lines express equivalent amounts of palladin protein.  C.) 
Expression of palladin isoforms in the pancreatic epithelial cell lines and normal fibroblasts 
compared to tumor-associated fibroblasts (TAF).  Tumor-associated fibroblasts express as 
many as five different isoforms, as shown by the arrows.  The numbers correspond to the 
numbered isoforms in Figure 1.  (Blots performed by Silvia Goicoechea, TAFs from Anil 
Rustgi). 
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Figure 3: Palladin Staining in Immunohistological Sections Shows Palladin is Localized 
to the Stromal Cells Surrounding Pancreatic Tumors  
 
 
Figure 3: Immunohistochemistry of paraffin-embedded human tissue sections with 
peroxidase staining of palladin and counterstain with hematoxylin from normal (A, E), 
chronic pancreatitis (B, F), and adenocarcinoma (C, G) magnified at 20X and 
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adenocarcinoma magnified at 40X (D, H).  In panel A, the staining is done with the 
polyclonal Commercial antibody; while in panel B, the staining is done with the monoclonal 
1E6 antibody.  Staining intensity is indicated by a more intense peroxidase reaction (Staining 
performed by Dave Cowan). 
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Figure 4: Immunohistological Scoring of Palladin in Normal Pancreas, Chronic 
Pancreatitis, and Adenocarcinoma, by Antibody 
 
 
 
Figure 4: Pathological scoring of palladin staining of immunohistochemistry sections from 
normal pancreas(blue bars, N), pancreatitis(yellow bars, P), and adenocarcinoma(red bars, T)  
A.) Scoring of palladin staining strictly in epithelial cells from these sections.  The average 
numerical score is indicated on the y-axis, while the different palladin antibodies are on the 
x-axis. Height of bars represents the intensity of palladin staining.  B.) Palladin staining 
strictly in stromal cells graded by the same scoring rubric and antibodies. (Scoring by Dr. 
Keith Volmar) 
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Figure 5: Western Blots of Tissue from Normal Pancreas, Invasive Pancreatic Tumors, 
and Less Invasive Pancreatic Tumors 
 
Figure 5:  A.)Western blot analysis of whole tumor and normal pancreas samples with 
multiple palladin antibodies.  Lanes 1 and 2 are normal pancreas; lanes 3-5 are pancreatic 
adenocarcinoma, and lanes 6 and 7 are less invasive pancreatic tumors.  The monoclonal 
antibodies 1E6 and 4D10 are used along with the polyclonal antibodies Commercial and 622.  
GAPDH is used as a loading control.  B.) Quantification, in arbitrary units, of the Western 
blot lane intensities with the 1E6 antibody.  N=normal pancreas, IT=invasive tumor, 
NIT=non-invasive tumor.  Palladin levels are higher in the adenocarcinoma samples, 
compared to the less invasive, non-adenocarcinoma samples (Western blots by Silvia 
Goicoechea). 
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Figure 6: Immunofluorescence of Primary Pancreatic Tumor Section with Palladin and 
the Marker for Activated Fibroblasts, α-Smooth Muscle Actin 
 
 
 
 
Figure 6: Sections of primary pancreatic tumor were double-labeled with the Commercial 
palladin antibody (red) and the marker of activated fibroblasts, α-smooth muscle actin 
(green).  The band of staining occurs in the nest of tumor-associated fibroblasts surrounding 
the tumor cells, denoted by the white arrows (Staining by Christianna Stack). 
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